Standardized Data File - Appendix 2
Measure Specifications

Version 2020

Updated 10/5/2021
# Appendix 2 Table of Contents

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKI-01</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>BP-01</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>BP-02</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>BP-03</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>Fluid-01-C</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Fluid-01-NC</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>MED-01</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>GLU-01</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>GLU-02</td>
<td></td>
<td>32</td>
</tr>
<tr>
<td>GLU-03</td>
<td></td>
<td>36</td>
</tr>
<tr>
<td>GLU-04</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>GLU-05</td>
<td></td>
<td>46</td>
</tr>
<tr>
<td>CARD-01</td>
<td></td>
<td>51</td>
</tr>
<tr>
<td>CARD-02</td>
<td></td>
<td>55</td>
</tr>
<tr>
<td>NMB-01</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>NMB-02</td>
<td></td>
<td>63</td>
</tr>
<tr>
<td>PONV-01</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>PONV-02</td>
<td></td>
<td>75</td>
</tr>
<tr>
<td>PONV-03</td>
<td></td>
<td>82</td>
</tr>
<tr>
<td>PUL-01</td>
<td></td>
<td>86</td>
</tr>
<tr>
<td>PUL-02</td>
<td></td>
<td>90</td>
</tr>
<tr>
<td>PUL-03</td>
<td></td>
<td>94</td>
</tr>
<tr>
<td>PAIN-01-peds</td>
<td></td>
<td>98</td>
</tr>
<tr>
<td>PAIN-02</td>
<td></td>
<td>103</td>
</tr>
<tr>
<td>SUS-01</td>
<td></td>
<td>107</td>
</tr>
<tr>
<td>TEMP-01</td>
<td></td>
<td>111</td>
</tr>
<tr>
<td>TEMP-02</td>
<td></td>
<td>117</td>
</tr>
<tr>
<td>TEMP-03</td>
<td></td>
<td>121</td>
</tr>
<tr>
<td>TRAN-01</td>
<td></td>
<td>126</td>
</tr>
<tr>
<td>TRAN-02</td>
<td></td>
<td>131</td>
</tr>
<tr>
<td>ABX-01</td>
<td></td>
<td>135</td>
</tr>
<tr>
<td>BP-04-OB</td>
<td></td>
<td>140</td>
</tr>
<tr>
<td>GA-01-OB</td>
<td></td>
<td>144</td>
</tr>
</tbody>
</table>
Measure Abbreviation
AKI-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of cases that the baseline creatinine increases more than 1.5 times within 7 postoperative days or the baseline creatinine level increases by \( = 0.3 \text{ mg/dL} \) within 48 hours postoperatively.

Inclusions
All anesthetic cases.

Exclusions
- ASA 5 & 6
- Patients with pre-existing renal (stage 4 or 5) failure based upon BSA-Indexed EGFR < 30 mL/min/1.73m^2
- Patients undergoing procedures affecting kidneys
  - Urologic surgery on kidney/ureter – CPT 00862, 00864, 00870, 00872, 00873, 00865, 00908, 00910, 00912, 00914, 00916, 00918, 00860, 00942
  - Renal & Liver Transplants – CPT 00868, 00796
- Non-Operative Procedures:
  - Obstetric Non-Operative Procedures – CPT 01958
  - Labor Epidurals as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)'
  - Pain Procedures – CPT 01991, 01992, 01996
  - Procedure Type: ECT
- Patients where a creatinine lab is not available within 7 postoperative days.
- Patients that do not have a baseline creatinine within 60 days preoperatively.
- For patients with more than one case in a 7-day period, the first case will be excluded if a postop creatinine is not documented for that first case. For example, a patient that has surgery twice in a 7-day period, the first surgery is excluded if a creatinine is not drawn in between cases.
- Case duration less than 45 minutes. See ‘Other Measure Build Details’ for Case Duration algorithm.
- Cases where the ‘Anesthesia End Time’ precedes ‘Anesthesia Start Time’ will be excluded and marked 'invalid'
Success
1. The creatinine level does not go above 1.5x the baseline creatinine within 7 days post-op
2. The creatinine level does not increase by ≥ 0.3 mg/dL obtained within 48 hours after anesthesia end.

Other Measure Build Details
Only valid creatinine values (≥0.2 mg/dL and ≤25.00 mg/dL) used. Method for calculating EGFR dependent on age and availability of patient race data:

Adult patients >18 years old:

- Sites with race data: CKD-EPI EGFR = 141 x min(Scr/κ, 1)α x max(Scr/κ, 1)-1.209 x (0.993)Age x (1.018 if female) x (1.159 if black)
  - Scr indicates the serum creatinine in mg/DL
  - κ = 0.7 for females, 0.9 for males; for missing gender data, assume female
  - α = -0.329 for females, -0.411 for males; for missing gender data, assume female
  - Age = age in years
  - min indicates the minimum of Scr/κ or 1
  - max indicates the maximum of Scr/κ or 1

Risk of progression to CKD is available per case in the 'Measure Case Report Tool'. Further details available here.

Responsible Provider
1. The provider signed in during the case when the BP 01 measure failed (it is possible to have more than one provider).
2. If there is no failure for the BP 01 measure, then the responsible provider is the provider signed in the longest.

Threshold
≤10%

MPOG Concept IDs Required
Creatinine Lab Concept ID

- 5002 Formal lab - Creatinine, Serum/Plasma

Ht/Wt MPOG Concept IDs

- 70257 Physical Exam - Height (cm)
- 70258 Physical Exam - Height (in)
- 70264 Physical Exam - Weight (kg)
- 70265 Physical Exam - Weight (lb)

Race MPOG Concept IDs modified

- 4000 Unknown Race
- 4001 Hispanic, White
- 4002 Hispanic, Black
- 4003 Hispanic, Color Unknown
- 4004 Black, not of Hispanic Origin
Phenotypes Used

- AKI - Risk of Progression to CKD (requires login)
- Case Duration
- DiagnosesCleaned (No phenotype browser page)
- Measure: BP-01
- PrimaryProvider
- Total blood administered as PRBC, Derived (ml)
- Total Colloid Administered, Raw (ml)
- Total Crystalloid Administered, Raw (ml)
- Total Estimated Blood Loss (EBL)
- Vasopressor Infusion
- VasopressorBolus (requires login)

Rationale

Acute kidney injury is a serious complication following non-cardiac surgery and is associated with an increased risk of in-hospital mortality. The development of AKI is known to increase patient care demands, accounting for 20% of intensive care unit (ICU) admissions, and significantly increasing hospital cost, length of stay, and mortality. Definitions and classification schema for AKI vary across current literature; most commonly, these include the Risk/Injury/Failure/Loss/End-stage (RIFLE), Acute Kidney Injury Network (AKIN), and Kidney Disease-Improving Global Outcomes (KDIGO) criteria. This measure most closely aligns with KDIGO AKI criteria, with exceptions of: a) not considering postoperative urine output or renal replacement therapy components of the definition (data are commonly unavailable); b) not considering cases in which a ≥ 0.3 mg/dL increase in serum creatinine level occurred greater than 48 hours but less than 7 days postoperative.

Risk Adjustment

To evaluate provider-level risk adjustment we will calculate the observed to expected outcomes ratio (O/E). The O/E is calculated using a logistic regression model and predicts (given a set list of dependent patient and hospital level variables) the expected probability of having a kidney injury. We adjust for surgery risk score, emergent procedures, ASA, gender, age, body mass index, laboratory values, and teaching versus private hospital. Patient specific comorbidities are evaluated as well.

References

Measure Abbreviation
BP-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases where intraoperative hypotension (MAP < 55 mmHg) was sustained for less than 20 minutes.

Measure Time Period
Intraoperative. See 'Other Measure Build Details' for more information

Inclusions
All patients requiring general anesthesia or monitored anesthesia care (MAC).

Exclusions
- Patients < 18 years old
- ASA 5 and 6 cases
- Baseline MAP < 60 mmHg (Highest MAP documented in preop under MPOG concepts 71120, 70211, 70212)
- Daily Hospital Management for Epidural (CPT: 01996)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals as determined by the MPOG 'Obstetric Anesthesia Type' phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)'
- Obstetric Non-Operative Procedures with procedure text: “Labor Epidural”
- Organ Harvest (CPT:01990
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- CABG without pump (CPT: 00566)
- Heart Transplant (CPT: 00580)
- Liver Transplants (see ProcedureTypeTransplantLiver phenotype)
- Lung Transplants (see ProcedureTypeTransplantLung phenotype)
- Unlisted Anesthesia Procedures (CPT: 01999)
Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

Success
- MAP <55mmHG that does not exceed cumulative time of 20 minutes OR
- MAP >55mmHG throughout case length.

Other Measure Build Details
- BP 01 measures the cumulative time of Mean Arterial Pressure (MAP) <55mmHG for a given case and provider. BP 01 includes non-invasive and invasive blood pressure monitoring captured using automated and manually entered physiologic data.
- Instances where there are two blood pressure monitoring methods, the higher MAP will be used to determine measure compliance.
- Artifact readings will be identified and removed from final measurement calculation. Artifact processing: if systolic and diastolic blood pressures are present, the values must be at least 5 mmHg apart; otherwise the values will be excluded. MAP values less than 10 are excluded.
- Each incidence of MAP <55 will attribute the responsible provider for a max of 5 minutes
- To determine how many minutes the last BP documented accounts for, the difference between it the “Measure End Time” algorithm is used (see page 3). As with the duration of other BPs, this duration is also capped at 5 minutes.

Algorithm for determining Measure Start/End Times:

**Measure Start Time:**
First Blood Pressure Reading after the latest of these 3 times:
1. First documented Anesthesia Start time.
2. First documented Patient in Room time.
3. First documented Data Capture Start time.

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, 'Cesarean Delivery Start Time' is used as the 'Measure Start Time'

**Measure End Time:**
1. Patient Out of Room. If not available,
2. Data Capture End. If not available,
3. Anesthesia End.

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, the latest 'data capture end' is used as the 'Measure End Time' when appropriate (all other cases use logic from 'Data Capture End' phenotype)

**Responsible Provider**
All providers for a given case whose individual cumulative MAP < 55mmHG exceeds the 20 minute timeframe
Threshold
90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Concept ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3011</td>
<td>BP Sys Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3040</td>
<td>BP Mean Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3012</td>
<td>BP Dias Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3041</td>
<td>BP Sys Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>3013</td>
<td>BP Mean Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3042</td>
<td>BP Dias Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>3015</td>
<td>BP Sys Non-invasive</td>
</tr>
<tr>
<td>3043</td>
<td>BP Mean Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>3020</td>
<td>BP Dias Non-invasive</td>
</tr>
<tr>
<td>3046</td>
<td>BP Sys Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3025</td>
<td>BP Mean Non-invasive</td>
</tr>
<tr>
<td>3047</td>
<td>BP Dias Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3026</td>
<td>BP Sys Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3048</td>
<td>BP Mean Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3027</td>
<td>BP Dias Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3475</td>
<td>BP Sys Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3028</td>
<td>BP Mean Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3476</td>
<td>BP Dias Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3030</td>
<td>BP Sys Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3477</td>
<td>BP Mean Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3035</td>
<td>BP Dias Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3041</td>
<td>BP Sys Invasive Unspecified Site 2</td>
</tr>
</tbody>
</table>

Data Diagnostics Affected

- Percentage of Physiologic Observations with a Meaningful Type Mapping
- Percentage of Cases with Invasive Blood Pressure
- Percentage of Cases with Non-invasive Blood Pressure
- Percentage of Cases with Physiologic Observations
- Percentage of Physiologic Rows that are Machine Captured
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used

- Anesthesia Left Bound (requires login)
- Anesthesia Right Bound (requires login)
- Baseline Blood Pressure - Mean
- Blood Pressure Observations
- Cesarean Delivery Start Time for Conversions
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Liver Transplant
- Procedure Type: Lung Transplant
- Procedure Type: Non-Operative

Rationale
Intraoperative hypotension is associated with compromised organ perfusion and puts patients at risk for post-operative mortality, cardiac adverse events (CAEs), acute kidney injury, and stroke. Multiple studies
have demonstrated the association of a decreased mean arterial pressure and postoperative morbidity and mortality. One retrospective review included 33,000 non-cardiac surgical patients and determined that a mean arterial pressure less than 55mmHg predicted CAEs and adverse renal-related outcomes. This was confirmed by a distinct investigation of 5000 patients using invasive blood pressure measurement.

Risk Adjustment
Not Applicable

References
Measure Abbreviation
BP-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases where gaps greater than 10 minutes in blood pressure monitoring are avoided.

Measure Time Period
Intraoperative. See ‘Other Measure Build Details’ for more information

Inclusions
All patients receiving anesthesia care by an anesthesiology provider, regardless of primary anesthesia technique.

Exclusions
- ASA 5 and 6.
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals as determined by the MPOG ‘Obstetric Anesthesia Type' phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)'
- Diagnostic Procedures (CPT: 01922)
- MRI Rooms (Rooms tagged as Radiology-MRI)
- MRI with procedure text:
  - MRI
  - MR Head
  - MR Brain
  - MR Chest
  - MR Torso
  - MR Abdomen
  - MR Lumbar
  - MR Spine
  - MR Knee
  - MR Femur
  - MR Abdomen
  - OFFSITE - RADIOLOGY PROCEDURE
Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

Success
Blood pressure monitoring with ≤10-minute gap in measurement interval.

Other Measure Build Details
BP 02 measures the avoidance of blood pressure monitoring gaps greater than ten minutes. Timely blood pressure readings are an essential component of anesthesia vigilance. A measurement gap will be recorded for cases that have greater than ten minutes between consecutive blood pressure readings. The measure will capture non-invasive and invasive BP measurements.

Algorithm for determining Measure Start/End Times:

**Measure Start Time:**
First Blood Pressure Reading after the latest of these 3 times:
1. First documented Anesthesia Start time.
2. First documented Patient in Room time.
3. First documented Data Capture Start time.

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, 'Cesarean Delivery Start Time' is used as the 'Measure Start Time'

**Measure End Time:**
1. Patient Out of Room. If not available,
2. Data Capture End. If not available,
3. Anesthesia End

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, the latest ‘data capture end’ is used as the ‘Measure End Time' when appropriate (all other cases use logic from 'Data Capture End' phenotype)

Responsible Provider
Individual signed into case at the 11th minute of identified measurement gap. Providers signed in for ≤ 10 minutes from the measure start time will be excluded.

Threshold
90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Concept ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3011</td>
<td>BP Sys Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3012</td>
<td>BP Dias Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3013</td>
<td>BP Mean Invasive Unspecified Site 1</td>
</tr>
<tr>
<td>3015</td>
<td>BP Sys Non-invasive</td>
</tr>
<tr>
<td>3040</td>
<td>BP Mean Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3041</td>
<td>BP Sys Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>3042</td>
<td>BP Dias Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>3043</td>
<td>BP Mean Invasive Unspecified Site 2</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>3020</td>
<td>BP Dias Non-invasive</td>
</tr>
<tr>
<td>3025</td>
<td>BP Mean Non-invasive</td>
</tr>
<tr>
<td>3026</td>
<td>BP Sys Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3027</td>
<td>BP Dias Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3028</td>
<td>BP Mean Invasive Unspecified Site 4</td>
</tr>
<tr>
<td>3030</td>
<td>BP Sys Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3035</td>
<td>BP Dias Arterial Line (Invasive, Peripheral)</td>
</tr>
<tr>
<td>3046</td>
<td>BP Sys Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3047</td>
<td>BP Dias Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3048</td>
<td>BP Mean Invasive Unspecified Site 3</td>
</tr>
<tr>
<td>3049</td>
<td>BP Sys Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3047</td>
<td>BP Dias Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3047</td>
<td>BP Mean Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3047</td>
<td>BP Sys Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3048</td>
<td>BP Dias Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3049</td>
<td>BP Mean Invasive Unspecified Site 5</td>
</tr>
<tr>
<td>3049</td>
<td>BP Sys Invasive Unspecified Site 5</td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**
- Percentage of Physiologic Observations with a Meaningful Type Mapping
- Percentage of Cases with Invasive Blood Pressure
- Percentage of Cases with Non-invasive Blood Pressure
- Percentage of Cases with Physiologic Observations
- Percentage of Physiologic Rows that are Machine Captured
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

**Phenotypes Used**
- Anesthesia Left Bound (requires login)
- Anesthesia Right Bound (requires login)
- ASA Class
- Blood Pressure Observations
- Cesarean Delivery Start Time for Conversions
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: MRI
- Procedure Type: Non-Operative

**Rationale**
The American Society of Anesthesiologist (ASA) standards for basic anesthetic monitoring includes an evaluation of blood pressure at least every five minutes in an effort to ensure adequate circulatory function during anesthesia. A retrospective study including 130,000 general anesthesia cases confirmed that blood pressure gaps greater than six and ten minutes are associated with a higher incidence of a patient transitioning into hypotension, leading to an increased risk of developing kidney or myocardial injury postoperatively. Extenuating circumstances where BP is not quantitatively measured every five minutes should be documented in the patient’s medical record.1-3

Hypotension is strongly associated with mortality, acute kidney injury, and myocardial ischemia. The avoidance of hypotension requires the timely and frequent measurement of blood pressure.

**Risk Adjustment**
Not applicable
References
Measure Abbreviation
BP-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases where intraoperative hypotension (MAP < 65 mmHg) was sustained for less than 15 minutes

Measure Time Period
Intraoperative. See ‘Other Measure Build Details’ for more information

Inclusions
All patients requiring anesthesia, general, neuraxial, monitored anesthesia care (MAC), or regional.

Exclusions
- Patients < 18 years old
- ASA 5 and 6 cases
- Baseline MAP < 65 mmHg (Highest MAP documented under MPOG concepts 71120, 70211, 70212)
- Daily Hospital Management for Epidural (CPT: 01996)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals as determined by the MPOG 'Obsteric Anesthesia Type' phenotype results 'Labor Epidural' and ‘Conversion (Labor Epidural Portion)'
- Organ Harvest (CPT:01990)
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- CABG without pump (CPT: 00566)
- Heart Transplant (CPT: 00580)
- Liver Transplants
- Lung Transplants
- Unlisted Anesthesia Procedures (CPT: 01999)
- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’
Success
- MAP <65mmHG that does not exceed cumulative time of 15 minutes OR
- MAP >65mmHG throughout case length.

Other Measure Build Details
- BP 03 measures the cumulative time of Mean Arterial Pressure (MAP) <65mmHG for a given case and provider. BP 03 includes non-invasive and invasive blood pressure monitoring captured using automated and manually entered physiologic data.
- Instances where there are two blood pressure monitoring methods, the higher MAP will be used to determine measure compliance.
- Artifact readings will be identified and removed from final measurement calculation. Artifact processing: if systolic and diastolic blood pressures are present, the values must be at least 5 mmHg apart; otherwise the values will be excluded. MAP values less than 10 are excluded.
- Each incidence of MAP <65 will attribute the responsible provider for a max of 5 minutes
- To determine how many minutes the last BP documented accounts for, the difference between the time of the blood pressure and the “Measure End Time” algorithm is used. As with the duration of other BPs, this duration is also capped at 5 minutes.

Measure Start Time:
First Blood Pressure Reading after the latest of these 3 times:
1. First documented Anesthesia Start time.
2. First documented Patient in Room time.
3. First documented Data Capture Start time.

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, ‘Cesarean Delivery Start Time’ is used as the ‘Measure Start Time’

Measure End Time:
1. Patient Out of Room. If not available,
2. Data Capture End. If not available,
3. Anesthesia End.

* For labor epidurals which convert to cesarean deliveries where the procedures are combined under one case ID, the latest 'data capture end' is used as the 'Measure End Time' when appropriate (all other cases use logic from 'Data Capture End' phenotype)

Responsible Provider
All providers for a given case whose individual cumulative MAP < 65mmHG exceeds the 15-minute timeframe.

Threshold
90%

MPOG Concept IDs Required

| 3011 | BP Sys Invasive Unspecified Site 1 |
| 3040 | BP Mean Arterial Line (Invasive, Peripheral) |
Data Diagnostics Affected

- Percentage of Physiologic Observations with a Meaningful Type Mapping
- Percentage of Cases with Invasive Blood Pressure
- Percentage of Cases with Non-invasive Blood Pressure
- Percentage of Cases with Physiologic Observations
- Percentage of Physiologic Rows that are Machine Captured
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used

- Anesthesia Left Bound (requires login)
- Anesthesia Right Bound (requires login)
- Baseline Blood Pressure - Mean
- Blood Pressure Observations
- Cesarean Delivery Start Time for Conversions
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Liver Transplant
- Procedure Type: Lung Transplant
- Procedure Type: Non-Operative

Rationale

Intraoperative hypotension (MAP < 65mmHg) is associated with compromised organ perfusion and puts patients at risk for post-operative mortality, cardiac adverse events (CAEs) and acute kidney injury (AKI). Multiple studies have addressed the impact of hypotension on patient outcomes and generally show less CAEs, AKI, and death by maintaining a MAP above 60-70mmHg. One retrospective cohort analysis, including 57,315 non-cardiac surgical patients, demonstrated a MAP of less than 65mmHg was associated with a higher incidence of myocardial and kidney injury and the duration of low MAP significantly increases the odds of the aforementioned outcomes. Furthermore, a retrospective review including 33,330 non-cardiac surgical patients determined that a MAP less than 65mmHg for any duration was associated with similar adverse outcomes

Date Published: 09/2019
Date Reviewed: 09/2019
Last Updated: 09/20/2021
Risk Adjustment
Not applicable.

References
Measure Abbreviation
FLUID-01-C

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cardiac cases in which colloids were not administered intraoperatively.

Measure Time Period
Anesthesia Start to Anesthesia End

Inclusions
All patients undergoing general anesthetics, spinals, and epidurals AND documentation of a cardiac case indicated by one of the following:

- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- An intraoperative note with one of the following MPOG concepts:
  - 50399 Cardiopulmonary bypass -- aortic clamp on/off note
  - 50409 Cardiopulmonary bypass terminated
  - 50410 Cardiopulmonary bypass initiated (full)
  - 50416 Cardiopulmonary bypass -- crossclamp and circulatory arrest time totals
  - 50417 Cardiopulmonary bypass -- Access cannula removed note
  - 50714 Cardiopulmonary bypass - Bypass start / stop event

Exclusions

Exclusions:

- Non-cardiac cases
- ASA 5 and 6 cases
- \( \geq 2L \) EBL
• ≥ 4 units PRBC transfusion
• Patients that are in prone position for more than 4 hours
• Patients that are in Trendelenburg position for more than 4 hours
• Patients with ascites

Success
Colloids are not administered during the case.

Other Measure Build Details
• The purpose of this measure is to identify the use of colloids for patients that likely do not need them in the cardiac surgery patient population. It is the expectation that providers will uphold the ASA’s Choosing Wisely program by avoiding colloids and using crystalloid instead when appropriate.
• Measure Start/End Time is defined as Anesthesia Start to Anesthesia End.

Responsible Provider
The provider signed in at the time of the colloid administration.

Threshold
None

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Colloid MPOG Concepts</th>
<th>Patient Position MPOG Concepts</th>
<th>Patient Dx MPOG Concepts</th>
</tr>
</thead>
<tbody>
<tr>
<td>10017</td>
<td>Albumin 25%</td>
<td>50136 Positioning- Patient Position</td>
</tr>
<tr>
<td>10018</td>
<td>Albumin 5%</td>
<td>50137 Positioning- Patient positioned in left lateral decubitus position</td>
</tr>
<tr>
<td>10557</td>
<td>Albumin 20%</td>
<td>50818 Patient positioned in right lateral decubitus position</td>
</tr>
<tr>
<td>10458</td>
<td>Hetastarch</td>
<td>Blood Administration MPOG Concepts</td>
</tr>
<tr>
<td>10459</td>
<td>Pentastarch</td>
<td>10489 Packed Red Blood Cells-Autologous</td>
</tr>
<tr>
<td>10601</td>
<td>Hydroxyethyl Starch 130/0.4 6% in 0.9% Saline (Voluven)</td>
<td>10490 Packed Red Blood Cells-Homologous</td>
</tr>
</tbody>
</table>
Data Diagnostics Affected
- Percentage of Cases with any Fluid Recording
- Percentage of Fluids with a Meaningful Fluid Mapping
- Percentage of Cases with Colloids Administered

Phenotypes Used
- ASA Class
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Non-Operative
- ProcedureTypeCardiac
- ProcedureTypeIVF
- ProneOrTrendelenburg (requires login)
- Total Estimated Blood Loss (EBL)
- Units Transfused

Rationale
There is a lack of consistent evidence to suggest improved survival with the use of colloids as compared to crystalloids in the surgical population. Because colloids are more expensive than crystalloids, it is recommended that anesthesia providers avoid the use of colloids in most instances.

Risk Adjustment
Not applicable

References
Measure Abbreviation
FLUID-01-NC

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of non-cardiac cases in which colloids were not administered intraoperatively.

Measure Time Period
Anesthesia Start to Anesthesia End

Inclusions
- All patients undergoing general anesthetics, spinals, and epidurals.

Exclusions
- ASA 5 and 6 cases
- ≥2L EBL
- ≥ 4 units PRBC transfusion
- Patients that are in prone position for more than 4 hours
- Patients that are in Trendelenburg position for more than 4 hours
- Patients with ascites
- In Vitro Fertilization- Egg Retrieval cases (Surgical CPT: 58970, 58974, 58976)
- In Vitro Fertilization- Egg Retrieval Rooms (Rooms tagged as IVF-Only)
- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- Any cardiac case with an intraoperative note mapped to one of the following MPOG Concepts:
  - 50399 Cardiopulmonary bypass -- aortic clamp on/off note
  - 50409 Cardiopulmonary bypass terminated
  - 50410 Cardiopulmonary bypass initiated (full)
  - 50416 Cardiopulmonary bypass -- crossclamp and circulatory arrest time totals
  - 50417 Cardiopulmonary bypass -- Access cannula removed note
50714 Cardiopulmonary bypass - Bypass start / stop event
- Cases performed by cardiac surgical service: MPOG concept 80005.

Success
Colloids are not administered during the case.

Other Measure Build Details
- The purpose of this measure is to identify the use of colloids for patients that likely do not need them in the non-cardiac surgery patient population. It is the expectation that providers will uphold the ASA’s Choosing Wisely program by avoiding colloids and using crystalloid instead when appropriate.
- Measure Start/End Time is defined as Anesthesia Start to Anesthesia End.

Responsible Provider
The provider signed in at the time of the colloid administration.

Threshold
None

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Colloid MPOG Concepts</th>
<th>Patient Position MPOG Concepts</th>
<th>Patient Dx MPOG Concepts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10017</strong> Albumin 25%</td>
<td><strong>50136</strong> Positioning- Patient Position</td>
<td><strong>10500</strong> Ascites</td>
</tr>
<tr>
<td><strong>10018</strong> Albumin 5%</td>
<td><strong>50137</strong> Positioning- Patient positioned in left lateral decubitus position</td>
<td><strong>Estimated Blood Loss</strong> <strong>MPOG Concept</strong></td>
</tr>
<tr>
<td><strong>10557</strong> Albumin 20%</td>
<td><strong>50818</strong> Patient positioned in right lateral decubitus position</td>
<td><strong>10499</strong> EBL</td>
</tr>
<tr>
<td><strong>10458</strong> Hetastarch</td>
<td><strong>Blood Administration MPOG Concepts</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10459</strong> Pentastarch</td>
<td><strong>10489</strong></td>
<td>Packed Red Blood Cells-Autologous</td>
</tr>
<tr>
<td><strong>10601</strong> Hydroxyethyl Starch 130/0.4 6% in 0.9% Saline (Voluven)</td>
<td><strong>10490</strong></td>
<td>Packed Red Blood Cells-Homologous</td>
</tr>
<tr>
<td><strong>10605</strong> Hydroxyethyl Starch 6% in Lactated Solution (Hextend)</td>
<td><strong>10616</strong></td>
<td>Packed Red Blood Cells-Unknown Type</td>
</tr>
</tbody>
</table>
Data Diagnostics Affected

- Percentage of Cases with any Fluid Recording
- Percentage of Fluids with a Meaningful Fluid Mapping
- Percentage of Cases with Colloids Administered

Phenotypes Used

- ASA Class
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Non-Operative
- ProcedureTypeCardiac
- ProcedureTypeIVF
- ProneOrTrendelenburg (requires login)
- Total Estimated Blood Loss (EBL)
- Units Transfused

Rationale
There is a lack of consistent evidence to suggest improved survival with the use of colloids as compared to crystalloids in the surgical population. Because colloids are more expensive than crystalloids, it is recommended that anesthesia providers avoid the use of colloids in most instances. Evidence to support the use of hydroxyethyl starch to prevent ovarian hyperstimulation syndrome for In Vitro Fertilization cases has been published and these cases will be excluded.

Risk Adjustment
Not applicable.

References


Measure Abbreviation
MED-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of cases that required the use of naloxone or flumazenil for medication overdose.

Measure Time Period
Anesthesia Start to Anesthesia End

Inclusions
All cases in which opioids or benzodiazepines were administered during the intraoperative period.

Exclusions
- ASA 5 and 6 cases
- Patients not given opioids or benzodiazepines during the intraoperative period
- Cases where naloxone or flumazenil is administered before the first dose of opioid/benzodiazepine
- Patients that are still intubated at anesthesia end
- Procedure Type: ECT

Success
Administration of naloxone or flumazenil was not required for the case.

Special Considerations: If naloxone was given as an infusion AND as a bolus, the case is flagged due to the bolus. If naloxone is only given as an infusion, then the case is still evaluated for flumazenil. Patients receiving naloxone as in infusion indicate naloxone is being infused for pruritus for neuraxial technique.

Other Measure Build Details
MED 01 is an outcome measure that identifies intraoperative medication overdose by monitoring the administration of opioids and/or benzodiazepines and the administration of their reversals: flumanzenil and naloxone. Flumazenil is given for benzodiazepine overdose. Nalaxone is given for opioid overdose. The time period for this measure is Anesthesia Start to Anesthesia End. PACU time is not included currently.

Algorithm for determining Case Duration:
Case Start:

1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:

1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End.

Responsible Provider

The provider who is signed in for the longest portion of the case between Case Start and Case End. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.

Threshold

=5%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Opioid MPOG Concept IDs</th>
<th>Benzodiazepine MPOG Concept IDs</th>
<th>Reversal Medication MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10306</td>
<td>Morphine</td>
<td>10301</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Midazolam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10191</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flumazenil</td>
</tr>
<tr>
<td>10186</td>
<td>Fentanyl</td>
<td>10154</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diazepam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Naloxone</td>
</tr>
<tr>
<td>10219</td>
<td>Hydromorphone</td>
<td></td>
</tr>
<tr>
<td>10414</td>
<td>Sufentanil</td>
<td></td>
</tr>
</tbody>
</table>

Data Diagnostics Affected

- Percentage of Cases with Bolus Medications
- Percentage of Cases with an Intubation Note
- Percentage of Cases with an Extubation Note
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used
Rationale
Opioid and/or benzodiazepine administration can lead to respiratory depression, brain damage, and even death. Judicious use of opioids for patients that have planned extubation at end of case can avoid use of reversal agents and their side effects. For patients not meeting extubation requirements due to opioids or benzodiazepines, waiting until the effects wear off is preferable to reversal administration.

Risk Adjustment
Not applicable

References
Measure Abbreviation
GLU-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with perioperative glucose > 200 mg/dL with administration of insulin or glucose recheck within 90 minutes of original glucose measurement.

Measure Time Period
Intraoperative

Inclusions
- All patients with glucose level greater than 200 mg/dL between Anesthesia Start and Anesthesia End
- Patients with and without diagnosis of diabetes

Exclusions
- ASA 5 and 6 cases
- Patients < 12 years of age.
- Glucose measurements > 200 mg/dL within 90 minutes before Anesthesia End
- Outpatient cases with Anesthesia Start to Anesthesia end time less than 4 hours long
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- Cases where the 'Measure End Time' precedes 'Measure Start Time' will be excluded and marked 'invalid'

Success
- Administration of insulin within 90 minutes (either IV or sub Q routes) or
- Recheck of glucose level within 90 minutes

Other Measure Build Details
- Percentage of intraoperative glucose labs with perioperative glucose >200 with administration of insulin or glucose recheck within 90 minutes of original glucose measurement for the time period
between Anesthesia Start and Anesthesia End.

- For this quality measure, we selected a relatively high threshold glucose level (greater than 200 mg/dL) to alleviate concerns that patients undergoing general anesthetics are at risk of overtreatment and hypoglycemia.
- If two blood glucose levels are documented in the same minute, the lower blood glucose will be considered for this measure.

**Responsible Provider**

The provider signed in at the first glucose recheck or first administration of insulin. If neither occurred, then the responsible provider is the one signed in 90 minutes after the high glucose measurement.

**Threshold**

90%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Insulin MPOG Concept IDs</th>
<th>Glucose MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10229 Insulin Aspart</td>
<td>3361 POC- Glucose (Fingerstick)</td>
</tr>
<tr>
<td>10230 Insulin Glargine</td>
<td>3362 POC- Glucose (Unspecified Source)</td>
</tr>
<tr>
<td>10231 Insulin Novolin</td>
<td>3405 POC- Blood Gas-Glucose</td>
</tr>
<tr>
<td>10232 Insulin NPH</td>
<td>5003 Formal Lab-Glucose, Serum/Plasma</td>
</tr>
<tr>
<td>10233 Insulin Regular</td>
<td>5036 Formal Lab-Blood Gas, Glucose</td>
</tr>
<tr>
<td>10659 Insulin-Unspecified</td>
<td></td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**

- Percentage of Cases with Insulin Administration Mapped Correctly
- Percentage of Cases with POC Glucose Labs
- Percentage of Cases with a Lab Drawn during Anesthesia
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Fluids with a Meaningful Fluid Mapping

**Phenotypes Used**

- Admission Type
Rationale
Surgical and anesthetic stress increases hyperglycemia incidence in both diabetics and non-diabetics. Perioperative hyperglycemia is mediated by the release of proinflammatory cytokines (e.g., TNF-alpha and IL-6) and elevated concentrations of catecholamines, growth hormone, glucagon, and glucocorticoids. These mediators induce metabolic alterations in carbohydrate balance that alter peripheral glucose uptake and utilization, increase gluconeogenesis, depress glycogenesis, and induce glucose intolerance and insulin resistance. Hyperglycemia can also be drug induced (administration of steroids).

Acute hyperglycemia in the perioperative period is known to increase the incidence of wound infections, overall mortality, length of stay, acute kidney injury, and delayed wound healing. Use of insulin to correct perioperative hyperglycemia decreases the risk of hospital complications and mortality in cardiac and general surgery patients. The American Association of Clinical Endocrinologists and American Diabetes Association recommend a treatment threshold of 180 mg/dL in critically ill hospitalized patients and a preprandial blood glucose goal of 140 mg/dL in non-critically hospitalized ill patients. Patients undergoing anesthesia who are subject to tight glucose control are at greater risk of hypoglycemia as the effects of anesthesia can mask the symptoms of hypoglycemia and current methods of treatment and monitoring put patients at risk of overcorrection. A relatively high threshold glucose level (greater than 200 mg/dL) is used for this measure to alleviate concerns that patients undergoing general anesthetics are at risk of overtreatment and hypoglycemia. Blood glucose may be rechecked in one hour.

Risk Adjustment
Not applicable

References


Measure Abbreviation
GLU-02

Measure Type
Process

Description
Percentage of cases with perioperative glucose < 60 with administration of dextrose containing solution or glucose recheck within 90 minutes of original glucose measurement

Measure Time Period
Intraoperative

Inclusions
- All patients with glucose level less than 60 mg/dL between Anesthesia Start and Anesthesia End
- Patients with and without diagnosis of diabetes

Exclusions
- ASA 5 and 6 cases
- Glucose measurements < 60 mg/dL within 90 minutes before Anesthesia End
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- Cases where the 'Measure End Time' precedes 'Measure Start Time' will be excluded and marked 'invalid'

Success
- Administration of dextrose containing solution within 90 minutes (IV) OR
- Recheck of glucose level within 90 minutes

Other Measure Build Details
- Percentage of intraoperative glucose labs with perioperative glucose <60 with administration of dextrose containing solution or glucose recheck within 90 minutes of original glucose measurement for the time period between Anesthesia Start and Anesthesia End.

Responsible Provider
The provider signed in at the first glucose recheck or first administration of dextrose. If neither occurred, then the responsible provider is the one signed in 90 minutes after the low glucose measurement.
MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Dextrose MPOG Concept IDs</th>
<th>Glucose MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10152</td>
<td>3361</td>
</tr>
<tr>
<td>Dextrose</td>
<td>POC- Glucose</td>
</tr>
<tr>
<td></td>
<td>(Fingerstick)</td>
</tr>
<tr>
<td>10153</td>
<td>3362</td>
</tr>
<tr>
<td>Dextrose 50%</td>
<td>POC- Glucose</td>
</tr>
<tr>
<td></td>
<td>(Unspecified Source)</td>
</tr>
<tr>
<td>10460</td>
<td>3405</td>
</tr>
<tr>
<td>Dextrose / Water 5%</td>
<td>POC- Blood Gas-Glucose</td>
</tr>
<tr>
<td>10461</td>
<td>5003</td>
</tr>
<tr>
<td>Dextrose / Lactated Ringers 5%</td>
<td>Formal Lab-Glucose, Serum/Plasma</td>
</tr>
<tr>
<td>10462</td>
<td>5036</td>
</tr>
<tr>
<td>Dextrose / Water 10%</td>
<td>Formal Lab-Blood Gas, Glucose</td>
</tr>
<tr>
<td>10465</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline 5% / 0.225%</td>
<td></td>
</tr>
<tr>
<td>10466</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline 5% / 0.45%</td>
<td></td>
</tr>
<tr>
<td>10467</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline 5% / 0.9%</td>
<td></td>
</tr>
<tr>
<td>10468</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline w/KCl 5% / 0.45% + 20 MEQ/L</td>
<td></td>
</tr>
<tr>
<td>10469</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline w/KCl 5% / 0.9% + 20 MEQ/L</td>
<td></td>
</tr>
<tr>
<td>10470</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline 10% / 0.45%</td>
<td></td>
</tr>
<tr>
<td>10539</td>
<td></td>
</tr>
<tr>
<td>Dextrose 10% w/ Lactated Ringers</td>
<td></td>
</tr>
<tr>
<td>10548</td>
<td></td>
</tr>
<tr>
<td>Plasmalyte 148 w/ Dextrose 5%</td>
<td></td>
</tr>
<tr>
<td>10558</td>
<td></td>
</tr>
<tr>
<td>Dextrose / Saline w/KCl 5% / 0.225% + 20 MEQ/L</td>
<td></td>
</tr>
</tbody>
</table>
Data Diagnostics Affected
- Percentage of Cases with Insulin Administration Mapped Correctly
- Percentage of Cases with POC Glucose Labs
- Percentage of Cases with a Lab Drawn during Anesthesia
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Fluids with a Meaningful Fluid Mapping

Phenotypes Used
- Anesthesia CPT (Measures)
- ASA Class
- Glucose Observations Perioperative
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Obstetric Anesthesia Type
- Procedure Type: Non-Operative

Rationale
The American Diabetes Association uses an outpatient hypoglycemia definition of <70 mg/dL. Severe hypoglycemia in inpatients is considered <40 mg/dL. Acute hypoglycemia in the perioperative period can lead to inadequate supply of glucose to the brain, resulting in seizures, permanent brain damage, and death. In hospitalized diabetic patients, hypoglycemia has been associated with increased length of stay and mortality. The risk of negative sequelae related to hypoglycemia is reduced with early recognition and treatment of mild to moderate hypoglycemia (40-69 mg/dL). The common signs/symptoms of hypoglycemia are masked by general anesthesia, making vigilance and quick treatment especially important. Fasting patients with or without diabetes and diabetic patients treated with oral glycemic agents or insulin are at increased risk of perioperative hypoglycemia.

Perioperative hypoglycemia is a rare event typically caused by the following:

1. Insulin overdose, either by patient taking higher than normal doses on the morning of surgery or by providers giving more insulin than necessary
2. Septic or circulatory shock
3. Failure to monitor

Risk Adjustment
Not applicable

References


Measure Abbreviation
GLU-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with perioperative glucose > 200 mg/dL with administration of insulin or glucose recheck within 90 minutes of original glucose measurement.

Measure Time Period
Preop through PACU (see ‘Other Measure Build Details’ for more information)

Inclusions
- All patients with glucose level greater than 200 mg/dL
- Patients with and without diagnosis of diabetes

Exclusions
- ASA 5 and 6 cases
- Patients < 12 years of age.
- Glucose measurements > 200 mg/dL within 90 minutes before measure end (see ‘Other Measure Build Details’ for more information)
- Outpatient cases with Anesthesia Start to Anesthesia end time less than 4 hours long
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG ‘Obstetric Anesthesia Type’ Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

Success
- Administration of insulin within 90 minutes (either IV or sub Q routes) or
- Recheck of glucose level within 90 minutes

Other Measure Build Details
- Percentage of glucose labs with perioperative glucose >200 with administration of insulin or glucose
recheck within 90 minutes of original glucose measurement for the time period encompassing preop to PACU.

- If two blood glucose levels are documented in the same minute, the lower blood glucose will be considered for this measure
- Measure start time is determined by MPOG Phenotype 'Preop Start Time'
- Measure end time is determined by MPOG Phenotype 'PACU End Time'

**Responsible Provider**

Preop Time Period (preop start through anesthesia start): The first provider signed into the case

Intraop Time Period: The provider signed in at the first glucose recheck or first administration of insulin. If neither occurred, then the responsible provider is the one signed in 90 minutes after the high glucose measurement.

Postop Time Period (anesthesia end through PACU End): The last providers signed into the case

**Threshold**

90%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Insulin MPOG Concept IDs</th>
<th>Glucose MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10229 Insulin Aspart</td>
<td>3361 POC- Glucose (Fingerstick)</td>
</tr>
<tr>
<td>10230 Insulin Glargine</td>
<td>3362 POC- Glucose (Unspecified Source)</td>
</tr>
<tr>
<td>10231 Insulin Novolin</td>
<td>3405 POC- Blood Gas-Glucose</td>
</tr>
<tr>
<td>10232 Insulin NPH</td>
<td>5003 Formal Lab-Glucose, Serum/Plasma</td>
</tr>
<tr>
<td>10233 Insulin Regular</td>
<td>5036 Formal Lab-Blood Gas, Glucose</td>
</tr>
<tr>
<td>10659 Insulin- Unspecified</td>
<td>10752 Glucose Chew Tablet</td>
</tr>
<tr>
<td>10752 Insulin Lispro</td>
<td>10796 Glucose Gel 40%</td>
</tr>
<tr>
<td>10788 Insulin Detemir</td>
<td>10797 Glucose Gel 40%</td>
</tr>
</tbody>
</table>
Data Diagnostics Affected

- Percentage of Cases with Insulin Administration Mapped Correctly
- Percentage of Cases with POC Glucose Labs
- Percentage of Cases with a Lab Drawn during Anesthesia
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Fluids with a Meaningful Fluid Mapping

Phenotypes Used

- Admission Type
- Anesthesia CPT (Measures)
- ASA Class
- EndingProvider (No phenotype browser page)
- Glucose Observations Perioperative
- Measure Staff Sign Ins Extended (requires login)
- Obstetric Anesthesia Type
- PACU Start Time
- Starting Provider

Rationale

Surgical and anesthetic stress increases hyperglycemia incidence in both diabetics and non-diabetics.³ Perioperative hyperglycemia is mediated by the release of proinflammatory cytokines (e.g., TNF-alpha and IL-6) and elevated concentrations of catecholamines, growth hormone, glucagon, and glucocorticoids.⁴ These mediators induce metabolic alterations in carbohydrate balance that alter peripheral glucose uptake and utilization, increase gluconeogenesis, depress glycogenesis, and induce glucose intolerance and insulin resistance. Hyperglycemia can also be drug induced (administration of steroids).

Acute hyperglycemia in the perioperative period is known to increase the incidence of wound infections, overall mortality, length of stay, acute kidney injury, and delayed wound healing.⁵,⁶,⁷,⁸,⁹,¹⁰,¹¹,¹² Use of insulin to correct perioperative hyperglycemia decreases the risk of hospital complications and mortality in cardiac and general surgery patients.⁶,¹² The American Association of Clinical Endocrinologists and American Diabetes Association recommend a treatment threshold of 180 mg/dL in critically ill hospitalized patients and a preprandial blood glucose goal of 140 mg/dL in non-critically hospitalized ill patients.¹³ Patients undergoing anesthesia who are subject to tight glucose control are at greater risk of hypoglycemia as the effects of anesthesia can mask the symptoms of hypoglycemia and current methods of treatment and monitoring put patients at risk of overcorrection.⁴ A relatively high threshold glucose level (greater than 200 mg/dL) is used for this measure to alleviate concerns that patients undergoing general anesthetics are at risk of overtreatment and hypoglycemia.¹ Blood glucose may be rechecked in one hour.

Risk Adjustment

Not applicable

References


Measure Abbreviation
GLU-04

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with perioperative glucose <60 with administration of glucose or dextrose containing solution or glucose recheck within 90 minutes of original glucose measurement.

Measure Time Period
Preop through PACU (see ‘Other Measure Build Details’ for more information)

Inclusions
- All patients with glucose level less than 60 mg/dL
- Patients with and without diagnosis of diabetes

Exclusions
- ASA 5 and 6 cases
- Glucose measurements < 60 mg/dL within 90 minutes before measure end (‘See Other Measure Build Details’ for more information)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG ‘Obstetric Anesthesia Type’ Phenotype results 'Labor Epidural' and ‘Conversion (Labor Epidural Portion)’)
- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

Success
- Administration of glucose or dextrose containing solution within 90 minutes (IV)

OR
- Recheck of glucose level within 90 minutes
Other Measure Build Details

- Measure start time is determined by MPOG Phenotype 'Preop Start Time'
- Measure end time is determined by MPOG Phenotype 'PACU End Time'

Responsible Provider

Preop Time Period (preop start through anesthesia start): The first provider signed into the case

Intraop Time Period: The provider signed in at the first glucose recheck or first administration of insulin. If neither occurred, then the responsible provider is the one signed in 90 minutes after the high glucose measurement.

Postop Time Period (anesthesia end through PACU End): The last providers signed into the case

Threshold

90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Dextrose MPOG Concept IDs</th>
<th>Glucose MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10152</td>
<td>Dextrose</td>
</tr>
<tr>
<td>10153</td>
<td>Dextrose 50%</td>
</tr>
<tr>
<td>10460</td>
<td>Dextrose / Water 5%</td>
</tr>
<tr>
<td>10461</td>
<td>Dextrose / Lactated Ringers 5%</td>
</tr>
<tr>
<td>10462</td>
<td>Dextrose / Water 10%</td>
</tr>
<tr>
<td>10465</td>
<td>Dextrose / Saline 5% / 0.225%</td>
</tr>
<tr>
<td>10466</td>
<td>Dextrose / Saline 5% / 0.45%</td>
</tr>
<tr>
<td>10467</td>
<td>Dextrose / Saline 5% / 0.9%</td>
</tr>
<tr>
<td>10468</td>
<td>Dextrose / Saline w/KCl 5% / 0.45% + 20 MEQ/L</td>
</tr>
<tr>
<td>10469</td>
<td>Dextrose / Saline w/KCl 5% / 0.9% + 20 MEQ/L</td>
</tr>
<tr>
<td>3361</td>
<td>POC- Glucose (Fingerstick)</td>
</tr>
<tr>
<td>3362</td>
<td>POC- Glucose (Unspecified Source)</td>
</tr>
<tr>
<td>3405</td>
<td>POC- Blood Gas-Glucose</td>
</tr>
<tr>
<td>5003</td>
<td>Formal Lab-Glucose, Serum/Plasma</td>
</tr>
<tr>
<td>5036</td>
<td>Formal Lab-Blood Gas, Glucose</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>10470</td>
<td>Dextrose / Saline 10% / 0.45%</td>
</tr>
<tr>
<td>10539</td>
<td>Dextrose 10% w/ Lactated Ringers</td>
</tr>
<tr>
<td>10548</td>
<td>Plasmalyte 148 w/ Dextrose 5%</td>
</tr>
<tr>
<td>10558</td>
<td>Dextrose / Saline w/KCl 5%/ 0.225% + 20 MEQ/L</td>
</tr>
<tr>
<td>10559</td>
<td>Dextrose / Saline w/KCl 5%/ 0.45% + 40 MEQ/L</td>
</tr>
<tr>
<td>10588</td>
<td>Dextrose / Saline w/KCl 10%/ 0.225% + 20 MEQ/L</td>
</tr>
<tr>
<td>10594</td>
<td>Dextrose / Saline w/KCl 5%/ 0.45% + 10MEQ/L</td>
</tr>
<tr>
<td>10602</td>
<td>Dextrose / Saline 10% / 0.225%</td>
</tr>
<tr>
<td>10471</td>
<td>Total Parenteral Nutrition</td>
</tr>
<tr>
<td>10530</td>
<td>Peripheral Parenteral Nutrition</td>
</tr>
<tr>
<td>10777</td>
<td>Dextrose / Saline w/KCl 10% / 0.225% + 10MEQ/L</td>
</tr>
<tr>
<td>10778</td>
<td>Dextrose / Saline w/ KCl 10% / 0.45% + 10MEQ/L</td>
</tr>
<tr>
<td>10783</td>
<td>Dextrose / Saline 12.5% / 0.45%</td>
</tr>
<tr>
<td>10784</td>
<td>Dextrose / Water 25%</td>
</tr>
<tr>
<td>10785</td>
<td>Dextrose / Water 12.5%</td>
</tr>
<tr>
<td>10787</td>
<td>Dextrose / Water 3%</td>
</tr>
<tr>
<td>10780</td>
<td>Dextrose / Saline w/KCl 5% / 0.225% + 10MEQ/L</td>
</tr>
<tr>
<td>10781</td>
<td>Dextrose / Saline w/KCl 10% / 0.9% + 10MEQ/L</td>
</tr>
<tr>
<td>10786</td>
<td>Dextrose / Water 15%</td>
</tr>
<tr>
<td>10782</td>
<td>Dextrose / Saline w/KCl 5%/ 0.9% + 10 MEQ/L</td>
</tr>
<tr>
<td>10260</td>
<td>Dextrose / Sodium Acetate 10% / 19.5 MEQ</td>
</tr>
<tr>
<td>10613</td>
<td>Dextrose / Sodium Chloride 5% / 0.3%</td>
</tr>
<tr>
<td>10614</td>
<td>Dextrose / Sodium Chloride / Potassium Chloride 10% / 0.225% / 1.5 MEQ</td>
</tr>
<tr>
<td>Code</td>
<td>Solution</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>10615</td>
<td>Dextrose / Sodium Chloride / Potassium Chloride 5% / 0.45% / 1.5 MEQ</td>
</tr>
<tr>
<td>10622</td>
<td>Dextrose / Saline 10% / 0.9%</td>
</tr>
<tr>
<td>10623</td>
<td>Dextrose 25%</td>
</tr>
<tr>
<td>10647</td>
<td>Dextrose / Saline w/ KCL 5% / 0.9% + 40 MEQ/L</td>
</tr>
<tr>
<td>10667</td>
<td>Dextrose / Saline 12.5% / 0.225%</td>
</tr>
<tr>
<td>10672</td>
<td>Dextrose 10% / Unspecified Solution</td>
</tr>
<tr>
<td>10673</td>
<td>Heparin w/ Dextrose Solution</td>
</tr>
<tr>
<td>10674</td>
<td>Dextrose / Saline w/KCL 10% / 0.9% + 20 mEQ/L</td>
</tr>
<tr>
<td>10676</td>
<td>Dextrose 5% / Unspecified Solution</td>
</tr>
<tr>
<td>10715</td>
<td>Dextrose / Saline 12.5% / 0.9%</td>
</tr>
<tr>
<td>10723</td>
<td>Dextrose / Water w/ KCL 5% / 10mEQ/L</td>
</tr>
<tr>
<td>10724</td>
<td>Dextrose / Saline w/KCL 5% / 30 mEQ/L</td>
</tr>
<tr>
<td>10725</td>
<td>Dextrose 20%</td>
</tr>
<tr>
<td>10734</td>
<td>Dextrose / Sodium Acetate / Magnesium Sulfate 10% / 80mEQ / 10mEQ/L</td>
</tr>
<tr>
<td>10782</td>
<td>Dextrose / Saline w/ KCL 5% / 0.9% + 10mEQ</td>
</tr>
<tr>
<td>10786</td>
<td>Dextrose / Water 15%</td>
</tr>
<tr>
<td>10204</td>
<td>GLUCAGON</td>
</tr>
<tr>
<td>10796</td>
<td>Glucose Chew Tablet</td>
</tr>
<tr>
<td>10797</td>
<td>Glucose Gel 40%</td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**
- Percentage of Cases with Insulin Administration Mapped Correctly
- Percentage of Cases with POC Glucose Labs
- Percentage of Cases with a Lab Drawn during Anesthesia
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Medications with a Meaningful Medication Mapping
Phenotypes Used
- Anesthesia CPT (Measures)
- ASA Class
- EndingProvider (No phenotype browser page)
- Glucose Observations Perioperative
- Measure Staff Sign Ins Extended (requires login)
- Obstetric Anesthesia Type
- Starting Provider

Rationale
The American Diabetes Association uses an outpatient hypoglycemia definition of <70 mg/dL\(^6,7\). Severe hypoglycemia in inpatients is considered <40mg/dL\(^6\). Acute hypoglycemia in the perioperative period can lead to inadequate supply of glucose to the brain, resulting in seizures, permanent brain damage, and death. In hospitalized diabetic patients, hypoglycemia has been associated with increased length of stay and mortality.\(^5\) The risk of negative sequelae related to hypoglycemia is reduced with early recognition and treatment of mild to moderate hypoglycemia (40-69mg/dL)\(^6,8,9\). The common signs/symptoms of hypoglycemia are masked by general anesthesia, making vigilance and quick treatment especially important.\(^1\) Fasting patients with or without diabetes and diabetic patients treated with oral glycemic agents or insulin are at increased risk of perioperative hypoglycemia.\(^2,3\)

Perioperative hypoglycemia is a rare event typically caused by the following: \(^4\)

1. Insulin overdose, either by patient taking higher than normal doses on the morning of surgery or by providers giving more insulin than necessary
2. Septic or circulatory shock
3. Failure to monitor

Risk Adjustment
Not applicable

References


Measure Abbreviation
GLU-05

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with a blood glucose >200 mg/dL with documentation of insulin treatment

Measure Time Period
Preop start through PACU end

Inclusions
- All patients with a documented blood glucose level greater than 200 mg/dL between Preop Start and PACU End
- Patients with and without diagnosis of diabetes

Exclusions
- ASA 5 and 6 cases
- Patients < 12 years of age.
- Glucose measurements > 200 mg/dL within 90 minutes before measure end
- Outpatient cases with Anesthesia Start to Anesthesia end time less than 4 hours long
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- Documented blood glucose <200 within 90 minutes of a blood glucose >200 mg/dL excludes the glucose >200mg/dL
- Cases where the 'Measure End Time' precedes 'Measure Start Time' will be excluded and marked 'invalid'

Success
Administration of insulin within 90 minutes of blood glucose >200 mg/dL
Other Measure Build Details

Start Time - Preop Start as determined by MPOG Preop Start Time Phenotype

End Time - PACU End as determined by MPOG PACU End Time Phenotype

- Each blood glucose is evaluated separately. One instance of untreated blood glucose >200mg/dL will flag the case
- If a blood glucose is >200 mg/dL and any blood glucose within 90 minutes is <200 mg/dL, then the initial blood glucose will be excluded; the case will be excluded if no additional blood glucose values >200mg/dL are documented on the case
- If a blood glucose is >200 mg/dL and an insulin administration occurs within 90 minutes and there are no additional blood glucose values >200 mg/dL through PACU end, the case will pass.
- If blood glucose is >200 mg/dL and there is no insulin treatment within 90 minutes or documentation of a blood glucose <200mg/dL, the case will be flagged.
- Active infusion of an insulin drip at the time of high glucose will count as treatment for this measure. If no end time is available for an insulin infusion, the ‘measure end time’ will be considered the insulin infusion end time
- Sites not contributing preop and PACU data are not eligible to participate in this measure

Responsible Provider

Preop Time Period (preop start through anesthesia start): The first provider signed into the case

Intraop Time Period: The provider signed in at the first glucose recheck or first administration of insulin. If neither occurred, then the responsible provider is the one signed in 90 minutes after the high glucose measurement.

Postop Time Period (anesthesia end through PACU End): The last providers signed into the case

Threshold

90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Insulin MPOG Concept IDs</th>
<th>Glucose MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10229 Insulin Aspart</td>
<td>3361 POC- Glucose (Fingerstick)</td>
</tr>
<tr>
<td>10230 Insulin Glargine</td>
<td>3362 POC- Glucose (Unspecified Source)</td>
</tr>
<tr>
<td>10231 Insulin Novolin</td>
<td>3405 POC- Blood Gas-Glucose</td>
</tr>
<tr>
<td>10232 Insulin NPH</td>
<td>5003 Formal Lab-Glucose, Serum/Plasma</td>
</tr>
</tbody>
</table>
### Data Diagnostics Affected

- Percentage of Cases with Insulin Administration Mapped Correctly
- Percentage of Cases with POC Glucose Labs
- Percentage of Cases with a Lab Drawn during Anesthesia
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Fluids with a Meaningful Fluid Mapping

### Phenotypes Used

- Admission Type
- Anesthesia CPT (Measures)
- ASA Class
- EndingProvider (No phenotype browser page)
- Glucose Observations Perioperative
- Measure Staff Sign Ins Extended (requires login)
- Obstetric Anesthesia Type
- Starting Provider

### Rationale

Surgical and anesthetic stress increases hyperglycemia incidence in both diabetics and non-diabetics. Perioperative hyperglycemia is mediated by the release of proinflammatory cytokines (e.g., TNF-alpha and IL-6) and elevated concentrations of catecholamines, growth hormone, glucagon, and glucocorticoids. These mediators induce metabolic alterations in carbohydrate balance that alter peripheral glucose uptake and utilization, increase gluconeogenesis, depress glycogenesis, and induce glucose intolerance and insulin resistance. Hyperglycemia can also be drug induced (administration of steroids).

Acute hyperglycemia in the perioperative period is known to increase the incidence of wound infections, overall mortality, length of stay, acute kidney injury, and delayed wound healing. Use of insulin to correct perioperative hyperglycemia decreases the risk of hospital complications and mortality in cardiac and general surgery patients. The American Association of Clinical Endocrinologists and American Diabetes Association recommend a treatment threshold of 180 mg/dL in critically ill hospitalized patients and a preprandial blood glucose goal of 140 mg/dL in non-critically hospitalized ill patients. The Society for Ambulatory Anesthesia, American Association of Clinical Endocrinologists, The Society for Thoracic Surgery, and the Joint British Diabetes Society also recommend blood glucose management <180 mg/dL.

The ADA 2019 guidelines call for perioperative blood glucose ranges from 80-180mg/dL. Patients undergoing anesthesia are at risk of hypoglycemia as the effects of anesthesia can mask the symptoms of hypoglycemia; however, conventional glucose targets of <180 mg/dL have not been associated with significant risk of hypoglycemia. Frequent blood glucose monitoring after insulin administration is recommended. Intraoperative glucose levels should be checked every 2 hours or more frequent and insulin infusions should be monitored at least hourly. A relatively high threshold glucose level (greater than 200 mg/dL) is used for this measure to alleviate concerns that patients undergoing general anesthetics are at risk of overtreatment and hypoglycemia.
References


Measure Abbreviation
CARD-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of cases with elevated postoperative Troponin levels or documentation of perioperative myocardial injury.

Measure Time Period
Anesthesia End to 72 hours after Anesthesia End

Inclusions
All anesthetic cases.

Exclusions
- ASA 5 and 6 cases.
- Outpatient cases.
- Troponin I $\geq$ 0.01 ng/mL (or Troponin T $\geq$ 0.02 ng/mL) within 42 days prior to anesthesia start.\(^{*}\)
- Pacemaker insertions (CPT: 00530)
- Cardiac Ablation (CPT: 00537)
- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump and < 1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG without pump (CPT: 00566)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- Testing of cardioversion or defibrillator functions (CPT: 00534)
- Cardiac catheterization (CPT: 01920)

\(^{*}\)Rationale for excluding patient with troponin elevation within 42 days prior to date of surgery is based upon ACC/AHA guidelines recommending a delay in elective surgery for 6 weeks following myocardial infarction.\(^{4}\)
Success

In cases with Troponin I or Troponin T value(s) available within 72 hours after anesthesia end, all values must be less than or equal to the following:

- Troponin I (ctnl) ≤ 600 ng/L
- Troponin I (ctnl) ≤ 0.6 ng/mL
- Troponin T (hs-cTnT) ≤ 91 ng/L
- Troponin T (hs-cTnT) ≤ 91 pg/mL
- Troponin T (hs-cTnT) ≤ 0.091 ng/mL

If no Troponin I (or Troponin T) values are available within 72 hours after anesthesia end and there is no documentation of perioperative myocardial injury (MPOG Concepts: 90201, 90202), the case will not be flagged (ie we presume no myocardial injury).

Other Measure Build Details

- CARD 02 is an outcome measure that identifies patients that had elevated troponin levels (Troponin I > 0.6, Troponin T > 0.091) within 72 hours postoperatively.
- If another case starts within 72 hours, then the time window ends at anesthesia start of the subsequent case.
- For the preoperative Troponin I exclusion, cases with preoperative Troponin I values with ‘less than (<)’ included in the result will be included up to ‘<0.31.’ For example, preoperative Troponin I levels that are resulted as ‘<0.02’ will be included for the measure. However, a preoperative Troponin I value of 0.02 will be excluded. The rationale for this is each pathology department determines the lower bound for detecting Troponin I levels accurately. This is standardized to the health system but is not standard across all participating sites.
- For sites that use high sensitivity troponin T, although kinetics are different for Trop T and Trop I, cardiologists at The University of Michigan have shared that a hs-Trop T measurement of 30 pg/ml roughly correlates with the initial detectable level of Trop I (just above 0.1 ng/ml). An hs-Trop T of 140 pg/ml roughly correlates with a current Trop I value of 1.0 ng/ml. Using those endpoints in the slope intercept formula \( y = mx + b \), a Trop I value of 0.6 ng/ml roughly correlates to a hs-Trop T of 0.091 ng/ml
  - \( y = 0.00818x + 17.78 \)
  - \( 0.6 = 0.00818(x) + 17.78 \)
  - \( x = 90.9 \text{ pg/mL or } 0.091 \text{ ng/mL} \)

Algorithm for determining Case Duration:

Case Start:
1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:
1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End.
Responsible Provider

Providers assigned to patient for the longest duration of the case unless there are providers responsible for flagging BP 01 during case. In that case, BP 01 attribution takes precedence over longest duration. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.

Threshold

≤5%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Troponin MPOG Concept ID</th>
<th>Myocardial Injury MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>5011</td>
<td>90201</td>
</tr>
<tr>
<td>Formal lab – Cardiac Troponin I (cTnl ng/mL)</td>
<td>CPOM measure Cardiac Arrest</td>
</tr>
<tr>
<td>3396</td>
<td>90202</td>
</tr>
<tr>
<td>Formal lab – Cardiac Troponin I (cTnl ng/L)</td>
<td>CPOM measure Myocardial Ischemia</td>
</tr>
<tr>
<td>3397</td>
<td></td>
</tr>
<tr>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT ng/mL)</td>
<td></td>
</tr>
<tr>
<td>3392</td>
<td></td>
</tr>
<tr>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT ng/L)</td>
<td></td>
</tr>
<tr>
<td>3401</td>
<td></td>
</tr>
<tr>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT pg/mL)</td>
<td></td>
</tr>
</tbody>
</table>

Data Diagnostics Affected

- Percentage of Cases with Postoperative Troponin (Postoperative Troponin)
- Percentage of Cases with Professional Fee Procedure Codes (Pro Fee Procedures)
- Percentage of CPT Codes from Anesthesia Professional Fee Billing that are actually Anesthesia Codes (Anesthesia Codes)
- Percentage of Cases with a Meaningful Admission Type Mapping (Admission Type Mapping)
- Percentage of Cases with ASA Status (Cases with ASA Status)

Phenotypes Used

- Admission Type
Rationale
Postoperative myocardial infarction within 72 hours (as defined by a Troponin I level >3.6 times the 99th percentile upper reference limit, usually no greater than 1.00 ng/mL) is associated with a significantly increased risk of 30-day mortality. Furthermore, any amount of postoperative myocardial injury (as defined by a Troponin I level > 0.03 ng/mL) is an independent predictor of 30-day mortality. Preventing myocardial infarction is an important anesthetic goal.

Risk Adjustment
To evaluate provider-level risk adjustment we will calculate the observed to expected outcomes ratio (O/E). The O/E is calculated using a logistic regression model and predicts (given a set list of dependent patient and hospital level variables) the expected probability of having an elevated Troponin I level. We adjust for surgery risk score, emergent procedures, ASA, gender, age, body mass index, laboratory values, and teaching versus private hospital. Patient specific comorbidities are evaluated as well.

References
Measure Abbreviation
CARD-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of high cardiac risk cases with significantly elevated postoperative troponin levels.

Inclusions
- All high-risk surgeries* OR
- All anesthetic cases performed on patients with history of ischemic heart disease, congestive heart failure, cerebrovascular disease, diabetes requiring preoperative insulin, or chronic kidney disease (baseline Cr > 2.0 mg/dL).**

* High-risk surgeries include intraperitoneal, intrathoracic, or suprainguinal vascular procedures, as adapted from the Revised Cardiac Risk Index (RCRI) and identified by Anesthesia CPT codes:

<table>
<thead>
<tr>
<th>High Risk Surgery Type</th>
<th>Anesthesia CPT Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intraperitoneal</td>
<td>00730, 00754, 00756, 00790, 00792, 00794, 00796, 00797, 00840, 00844, 00846, 00848, 00851, 00855, 01140</td>
</tr>
<tr>
<td>Intrathoracic</td>
<td>00500, 00539, 00540, 00541, 00542, 00546, 00548, 00625, 00626, 01636, 01637</td>
</tr>
<tr>
<td>Suprainguinal Vascular</td>
<td>00216, 00350, 00670, 00770, 00880, 00882, 01650, 01652, 01654, 01656, 01770, 01772, 01925, 01926</td>
</tr>
</tbody>
</table>

** Comorbidities posing high cardiac risk are adapted from the Revised Cardiac Risk Index (RCRI) and are identified by Elixhauser Comorbidity Index variables (congestive heart failure, diabetes), preoperative lab values (baseline serum creatinine), or comorbidity-specific ICD-9/10 codes (ischemic heart disease, cerebrovascular disease):

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Specific Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive heart failure</td>
<td>Elixhauser Comorbidity – Congestive Heart Failure:</td>
</tr>
<tr>
<td>Condition</td>
<td>Measure</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Elixhauser Comorbidity – Diabetes (uncomplicated):</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>Elixhauser Comorbidity – Diabetes (complicated):</td>
</tr>
<tr>
<td>Ischemic Heart Disease</td>
<td>MPOG Phenotype – Coronary Artery Disease:</td>
</tr>
<tr>
<td></td>
<td><a href="https://collations.mpogresearch.org/Detail.aspx?name=Coronary%20Artery%20Disease">https://collations.mpogresearch.org/Detail.aspx?name=Coronary%20Artery%20Disease</a></td>
</tr>
<tr>
<td>Cerebrovascular Disease</td>
<td>MPOG Phenotype – Cerebrovascular Disease:</td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td>Most recent serum creatinine within 60 days &gt; 2.0 mg/dL</td>
</tr>
</tbody>
</table>

**Exclusions**
- ASA 5 and 6 cases.
- Outpatient cases
- Troponin I > 0.01 ng/mL within 42 days prior to anesthesia start
- Pacemaker insertions (CPT: 00530)
- Cardiac Ablation (CPT: 00537)
- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump < 1 year old (CPT: 00561)
- Cardiac surgery with pump (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG without pump (CPT: 00566)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- Testing of cardioversion or defibrillator functions (CPT: 00534)
- Cardiac catheterization (CPT: 01920)

*** Rationale for excluding patient with troponin elevation within 42 days prior to date of surgery is based upon ACC/AHA guidelines recommending a delay in elective surgery for 6 weeks following myocardial infarction.

**Success**
In cases with Troponin I or Troponin T value(s) available within 72 hours after anesthesia end, all values
must be less than or equal to the following:

- Troponin I (ctnl) ≤ 600 ng/L
- Troponin I (ctnl) ≤ 0.6 ng/mL
- Troponin T (hs-cTnT) ≤ 84 ng/L
- Troponin T (hs-cTnT) ≤ 84 pg/L
- Troponin T (hs-cTnT) ≤ 0.084 ng/mL

If no Troponin I (or Troponin T) values are available within 72 hours after anesthesia end and there is no documentation of perioperative myocardial injury (MPOG Concepts: 90201, 90202), the case will not be flagged (ie we presume no myocardial injury).

Other Measure Build Details

- CARD 03 is an outcome measure that identifies high cardiac risk patients that have severely elevated troponin levels within 72 hours postoperatively.
- If another case starts within 72 hours, then the time window ends at anesthesia start of the subsequent case.
- For the preoperative Troponin I exclusion, cases with preoperative Troponin I values with ‘less than (<)’ included in the result will be included up to ‘<0.31.’ For example, preoperative Troponin I levels that are resulted as ‘<0.02’ will be included for the measure. However, a preoperative Troponin I value of 0.02 will be excluded. The rationale for this is each pathology department determines the lower bound for detecting Troponin I levels accurately. This is standardized to the health system but is not standard across all participating sites.
- For sites that use high sensitivity troponin T, although kinetics are different for Trop T and Trop I, a hs-Trop T measurement of 30 pg/ml roughly correlates with the initial detectable level of Troponin I (just above 0.1 ng/ml). An hs-Trop T of 140 pg/ml roughly correlates with a current Trop I value of 1.0 ng/ml. Using those endpoints, a Trop I value of .6 ng/ml roughly correlates to a hs-Trop T of .84 pg/ml.

Responsible Provider

Providers assigned to patient longest duration of case unless there are providers who failed BP 01 (sustained MAP < 55 mmHg) during case. In that case, BP 01 failure takes precedence over longest duration.

Method for determining Responsible Provider:

1. Provider(s) who failed BP 01. If not applicable,
2. Provider(s) signed into the case for the longest duration.

Threshold

=5%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Troponin MPOG Concept ID</th>
<th>Myocardial Injury MPOG Concept IDs</th>
<th>Creatinine MPOG Concept ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>5011</td>
<td>Formal lab – Cardiac Troponin I (cTnl ng/mL)</td>
<td></td>
</tr>
<tr>
<td>3396</td>
<td>Formal lab – Cardiac Troponin I (cTnl ng/L)</td>
<td></td>
</tr>
<tr>
<td>3397</td>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT ng/mL)</td>
<td></td>
</tr>
<tr>
<td>3392</td>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT ng/L)</td>
<td></td>
</tr>
<tr>
<td>3401</td>
<td>Formal lab – High-sensitivity Cardiac Troponin T (hs-cTnT pg/mL)</td>
<td></td>
</tr>
</tbody>
</table>

### Data Diagnostics Affected
- Percentage of Cases with Postoperative Troponin (Postoperative Troponin)
- Percentage of Cases with Professional Fee Procedure Codes (Pro Fee Procedures)
- Percentage of CPT Codes from Anesthesia Professional Fee Billing that are actually Anesthesia Codes (Anesthesia Codes)
- Percentage of Cases with a Meaningful Admission Type Mapping (Admission Type Mapping)
- Percentage of Cases with ASA Status (Cases with ASA Status)

### Phenotypes Used
- Admission Type
- ComorbidityMpogCerebrovascularDisease (No phenotype browser page)
- Elixhauser Comorbidity - Congestive Heart Failure
- Elixhauser Comorbidity - Diabetes (Complicated)
- Elixhauser Comorbidity - Diabetes (Uncomplicated)
- Measure: BP-01
- MPOG Comorbidity - Coronary Artery Disease
- PrimaryProvider

### Rationale
Preventing myocardial infarction is an important anesthetic goal. Protecting against this outcome is particularly relevant among patients with comorbid conditions or undergoing surgeries at high risk of major adverse cardiac events.

Troponin I levels are accurate markers of myocardial infarction. Postoperative myocardial injury within 72 hours (as defined by a Troponin I level >2x the 99th percentile upper reference limit) is associated with a significantly increased risk of 30-day mortality. Furthermore, any amount of postoperative myocardial injury (as defined by a Troponin I level > 0.03 ng/mL) is an independent predictor of 30-day mortality. Adjusted
relative risk of death was 4.2 for patients with Troponin I $\geq 0.60$ ng/mL.

**Risk Adjustment**
To evaluate provider-level risk adjustment we will calculate the observed to expected outcomes ratio (O/E). The O/E is calculated using a logistic regression model and predicts (given a set list of dependent patient and hospital level variables) the expected probability of having an elevated Troponin I level. We adjust for surgery risk score, emergent procedures, ASA, gender, age, body mass index, laboratory values, and teaching versus private hospital. Patient specific comorbidities are evaluated as well.

**References**
Measure Abbreviation
NMB-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with a documented Train of Four (TOF) after last dose of non-depolarizing neuromuscular blocker.

Measure Time Period
Anesthesia Start to Earliest Extubation

Inclusions
All patients that have received either by bolus or infusion a non-depolarizing neuromuscular blocker (NMB) AND were extubated post-operatively or in the PACU. The following NMBs are included:

- Atracurium
- Cisatracurium
- Pancuronium
- Rocuronium
- Vecuronium

Exclusions
- ASA 5 and 6 cases.
- Patients that were not extubated in the immediate post-operative period.
- Patients not given NMBs.
- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- Any cardiac case with an intraoperative note mapped to one of the following MPOG Concepts:
  - 50399 Cardiopulmonary bypass -- aortic clamp on/off note
  - 50409 Cardiopulmonary bypass terminated
  - 50410 Cardiopulmonary bypass initiated (full)
Success
Documentation of a Train of Four count (1, 2, 3, or 4), sustained tetany, or TOF ratio provided by acceleromyography AFTER last dose or stopping of infusion of neuromuscular blocker and before earliest extubation. **Note:** A Train of Four value of ‘0’ is accepted for cases in which Sugammadex is administered for reversal.

Other Measure Build Details

**Responsible Provider**
The provider signed in at time of earliest extubation.

**Threshold**
90%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Neuromuscular Blocker Medications</th>
<th>Extubation</th>
<th>Train of Four</th>
</tr>
</thead>
<tbody>
<tr>
<td>10043 Atracurium</td>
<td>50127</td>
<td>3033</td>
</tr>
<tr>
<td></td>
<td>Intubation Extubated Awake or Deep</td>
<td>Train-of-four objective count (acceleromyography, electromyography, other)</td>
</tr>
<tr>
<td>10129 Cisatracurium</td>
<td>50202</td>
<td>3330</td>
</tr>
<tr>
<td></td>
<td>Emergence- Patient Extubated</td>
<td>Train-of-four (Subjective assessment)</td>
</tr>
<tr>
<td>10344 Pancuronium</td>
<td>50145</td>
<td>3485</td>
</tr>
<tr>
<td></td>
<td>Airway – Laryngeal mask airway removed (deep or awake)</td>
<td>Train-of-four (Acceleromyography)</td>
</tr>
<tr>
<td>10393 Rocuronium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10446 Vecuronium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**
- Percentage of Cases with a Non-Depolarizing NMB Administration
Phenotypes Used

- ASA Class
- Extubation Times
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Non-Operative
- ProcedureTypeCardiac
- Train Of Four Values

Rationale

Postoperative residual neuromuscular blockade can lead to significant complications. Several studies have found associations between the use of neuromuscular blockade agents (NMBA) and residual neuromuscular blockade in the recovery room. Adverse postoperative respiratory outcomes are even more frequent when patients receive NMBA and reversal agents are not used. A mainstay of residual blockade prevention continues to be monitoring to allow for detection, and use of reversal agents like neostigmine and Sugammadex. Due to variability in duration of muscle relaxants, even in defasciculating doses, we recommend that TOF is monitored when any non-depolarizing neuromuscular blockers are administered.

Risk Adjustment

Not Applicable

References

Measure Abbreviation
NMB-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Administration of Neostigmine, Sugammadex, and/or Edrophonium before extubation for cases with non-depolarizing neuromuscular blockade.

Measure Time Period
Anesthesia Start to Earliest Extubation

Inclusions
All patients that have received either by bolus or infusion a non-depolarizing neuromuscular blocker (NMB) AND were extubated post-operatively. The following NMBs were included:

- Atracurium
- Cisatracurium
- Pancuronium
- Rocuronium
- Vecuronium

Exclusions
- ASA 5 and 6 cases.
- Patients that were not extubated in the immediate post-operative period.
- Patients not given NMBs.
- Cardiac surgery without pump (CPT: 00560)
- Cardiac surgery with pump and <1 year old (CPT: 00561)
- Cardiac surgery with pump and > 1 year old (CPT: 00562)
- Cardiac surgery with hypothermic arrest (CPT: 00563)
- CABG with pump (CPT: 00567)
- Heart Transplant (CPT: 00580)
- Cases where patients (age > 12) received defasciculating doses of
  - Vecuronium ≤ 1mg
  - Cisatracurium ≤ 2mg
  - Rocuronium ≤ 10 mg
• Cases performed by cardiac surgical service: MPOG concept 80005.
• Any cardiac case with an intraoperative note mapped to one of the following MPOG Concepts:
  ○ 50399 Cardiopulmonary bypass -- aortic clamp on/off note
  ○ 50409 Cardiopulmonary bypass terminated
  ○ 50410 Cardiopulmonary bypass initiated (full)
  ○ 50416 Cardiopulmonary bypass -- crossclamp and circulatory arrest time totals
  ○ 50417 Cardiopulmonary bypass -- Access cannula removed note
  ○ 50714 Cardiopulmonary bypass - Bypass start / stop event

Success
Documentation of neostigmine, Sugammadex, and/or edrophonium before earliest extubation.

OR
A period of greater than 3 hours exists between last dose of non-depolarizing medication and extubation for patients ≥ 12 years old.

OR
A period of greater than 2 hours exists between last dose of non-depolarizing medication and extubation for patients <12 years old.

OR
An acceleromyography ratio of ≥ 0.9 documented after last dose of NMB and before earliest extubation.

Other Measure Build Details

Responsible Provider
The provider(s) signed in at time of earliest extubation.

Threshold
90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Neurmuscular Blocker Medications</th>
<th>Reversal Agents</th>
<th>Extubation</th>
<th>Train of Four</th>
</tr>
</thead>
<tbody>
<tr>
<td>10043 Atracurium</td>
<td>10170 Edrophonium</td>
<td>50127 Intubation Extubated Awake or Deep</td>
<td>3485 Train-of-four (Acceleromyography)</td>
</tr>
<tr>
<td>10129 Cisatracurium</td>
<td>10315 Neostigmine</td>
<td>50202 Emergence-Patient Extubated</td>
<td></td>
</tr>
</tbody>
</table>
Data Diagnostics Affected
- Percentage of Cases with a Non-Depolarizing NMB Administration
- Percentage of Cases with an Extubation Note
- Percentage of Cases with Neuromuscular Blocker Reversal Agents Administered
- Percentage of Medications with a Meaningful Medication Mapping
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used
- ASA Class
- Extubation Times
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Procedure Type: Non-Operative
- Procedure Type: Cardiac

Rationale
Postoperative residual neuromuscular blockade can lead to significant complications.\(^1,2\) Several studies have found associations between the use of neuromuscular blockade agents (NMBA) and residual neuromuscular blockade in the recovery room. Adverse postoperative respiratory outcomes are even more frequent when patients receive NMBA and reversal agents are not used. A mainstay of residual blockade prevention continues to be monitoring to allow for detection, and use of reversal agents like neostigmine and sugammadex.\(^3-5\) Due to variability in duration of muscle relaxants, even in defasciculating doses, we recommend that TOF is monitored when any non-depolarizing neuromuscular blockers are administered.

References
Measure Abbreviation
PONV-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with
administrative data sources such as professional fee and discharge diagnoses data. This measure is
explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of patients, aged 18 years and older, who undergo a procedure under an inhalational general
anesthetic, AND who have three or more risk factors for post-operative nausea and vomiting (PONV), who
receive combination therapy consisting of at least two prophylactic pharmacologic antiemetic agents of
different classes preoperatively or intraoperatively.

The purpose of this process of care measure is to reduce the incidence of postoperative nausea and
vomiting in adult surgical patients.

Measure Time Period
4 hours before Anesthesia Start to PACU start

Inclusions
• All patients, aged 18 years and older, who undergo any procedure including surgical, therapeutic, or
diagnostic under an inhalational general anesthetic between Anesthesia Start and Anesthesia End, AND who have three or more risk factors for PONV.
  ○ PONV Risk Factors:
    ▪ Female gender
    ▪ History of PONV
    ▪ History of motion sickness
    ▪ Non-smoker
    ▪ Intended administration of opioids for post-operative analgesia. This includes use of
      opioids given intraoperatively and whose effects extend into the post anesthesia care
      unit (PACU) or post-operative period, or opioids given in the PACU, or opioids given
      after discharge from the PACU.

Exclusions
• Patients <18 years old.
• Patients transferred directly to the ICU
• Liver Transplants (see ProcedureTypeTransplantLiver phenotype)
• Lung Transplants (see ProcedureTypeTransplantLung phenotype)
Procedures (by CPT): 00452, 00561, 00562, 00563, 00567, 00622, 00634, 01916, 01920, 01922, 01953, 01958, 01960, 01990, 01991, 01992, 01996, 01999

Obstetric Non-Operative Procedures (CPT: 01958)

Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')

Invalid cases where Measure End results prior to Measure Start

Success

Patient receives combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively or intraoperatively

Anti-emetic therapy: The recommended first- and second-line classes of pharmacologic anti-emetics for PONV prophylaxis in patients at moderate to severe risk of PONV include (but are not limited to):

- NK-1 Receptor Antagonists
- 5-Hydroxytryptamine (5-HT3) Receptor Antagonists
- Glucocorticoids
- Phenothiazines
- Phenylethylamines
- Butyrophenones
- Antihistamines
- Anticholinergics

Note: In addition, propofol infusion is accepted as one of the antiemetic options for this measure. The foregoing list of medications/drug names is based on clinical guidelines and other evidence. The specified drugs were selected based on the strength of evidence for their clinical effectiveness. This list of selected drugs may not be current. Physicians and other health care professionals should refer to the FDA’s web site page entitled “Drug Safety Communications” for up-to-date drug recall and alert information when prescribing medications.

Other Measure Build Details

- Values for flows and gases will be assessed and considered artifact if less than the following ranges and the patient did not receive any other inhalational general anesthetics greater than these ranges:
  - Nitrous Oxide Flows: <0.2 L/min
  - Isoflurane Insp %: <0.2%
  - Sevoflurane Insp %: <0.5%
  - Desflurane Insp %: <0.5%
  - Nitrous Oxide Insp % <15%

- If smoking status is not documented, patient is assumed to be a non-smoker and therefore is assigned at least one risk factor.

- This measure requires CPT codes to be transferred to the MPOG database for cases to be included. Those sites participating with this measure must have current pro fee procedure data in the MPOG Central database- refer to the flow diagram on page 10 of this specification for more details.

Algorithm for determining Measure End Time:

- Recovery Room In Date/Time. If not available then,
- Phase I Recovery Room In Date/Time. If not available then,
- Phase II Recovery Room In Date/Time. If not available then,
- Patient out of Room. If not available then,
- Data Capture End. If not available then,
Responsible Provider
Provider(s) signed in at Induction End.

Method for determining Responsible Provider:

1. Provider signed in at Anesthesia Induction End. If not available then,
2. Provider signed in at Anesthesia Induction Begin. If not available then,
3. Provider signed in at Procedure Start. If not available then,
4. Provider signed in at Patient in Room. If not available then,
5. Provider signed in Anesthesia Start.

Threshold
90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>General Inhalational Anesthetic MPOG Concept IDs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3297</td>
<td>Enflurane Exp %</td>
</tr>
<tr>
<td>3298</td>
<td>Enflurane Insp %</td>
</tr>
<tr>
<td>3006</td>
<td>Isoflurane actual consumption (ml)</td>
</tr>
<tr>
<td>3007</td>
<td>Desflurane actual consumption (ml)</td>
</tr>
<tr>
<td>3260</td>
<td>Isoflurane Exp %</td>
</tr>
<tr>
<td>3265</td>
<td>Isoflurane Insp %</td>
</tr>
<tr>
<td>3280</td>
<td>Desflurane Exp %</td>
</tr>
<tr>
<td>3285</td>
<td>Desflurane Insp %</td>
</tr>
<tr>
<td>50420</td>
<td>Cardiopulmonary bypass – Isoflurane vaporizer turned on</td>
</tr>
<tr>
<td>3008</td>
<td>Sevoflurane actual consumption (ml)</td>
</tr>
<tr>
<td>3270</td>
<td>Sevoflurane Exp %</td>
</tr>
<tr>
<td>3275</td>
<td>Sevoflurane Insp %</td>
</tr>
<tr>
<td>3503</td>
<td>Sevoflurane (mmHg)</td>
</tr>
<tr>
<td>3250</td>
<td>Nitrous Insp %</td>
</tr>
<tr>
<td>3255</td>
<td>Nitrous Exp %</td>
</tr>
</tbody>
</table>
### Antiemetic MPOG Concept IDs (by class)

#### Class: 5-Hydroxytryptamine (5-HT3) Receptor Antagonists

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10335</td>
<td>Ondansetron</td>
</tr>
<tr>
<td>10164</td>
<td>Dolasetron</td>
</tr>
<tr>
<td>10208</td>
<td>Granisetron</td>
</tr>
<tr>
<td>10711</td>
<td>Palonosetron</td>
</tr>
</tbody>
</table>

#### Anticholinergics

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10400</td>
<td>Scopolamine Patch</td>
</tr>
<tr>
<td>10399</td>
<td>Scopolamine</td>
</tr>
<tr>
<td>11040</td>
<td>Butylscopolamine</td>
</tr>
</tbody>
</table>

#### Antiemetic MPOG Concept IDs (by class)- Continued

#### Antihistamines

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10257</td>
<td>Dimenhydrinate</td>
</tr>
<tr>
<td>10160</td>
<td>Diphenhydramine</td>
</tr>
<tr>
<td>10635</td>
<td>Meclizine</td>
</tr>
</tbody>
</table>

#### Butyrophenones

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10169</td>
<td>Droperidol</td>
</tr>
<tr>
<td>10210</td>
<td>Haloperidol</td>
</tr>
</tbody>
</table>

#### Neurokinin-1 Receptor Agonists

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10035</td>
<td>Aprepitant</td>
</tr>
<tr>
<td>10719</td>
<td>Fosaprepitant</td>
</tr>
</tbody>
</table>

#### Phenothiazines

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10374</td>
<td>Promethazine</td>
</tr>
<tr>
<td>10373</td>
<td>Prochlorperazine</td>
</tr>
</tbody>
</table>

#### Steroids

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10147</td>
<td>Dexamethasone</td>
</tr>
<tr>
<td>10296</td>
<td>Methylprednisolone</td>
</tr>
</tbody>
</table>

#### Prokinetic

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10297</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>10377</td>
<td></td>
</tr>
<tr>
<td>Propofol (Infusion only)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PONV Medical Reason Exclusion MPOG Concept ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>50046</td>
</tr>
<tr>
<td>Medical Performance Exclusion- PONV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PONV Risk Factor- Smoking Status MPOG Concept IDs:</th>
</tr>
</thead>
<tbody>
<tr>
<td>70128</td>
</tr>
<tr>
<td>History- Social History- Tobacco</td>
</tr>
<tr>
<td>71100</td>
</tr>
<tr>
<td>History- Social History- Tobacco Details Pack Years</td>
</tr>
<tr>
<td>71110</td>
</tr>
<tr>
<td>History- Social History- Tobacco details Current vs Past</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PONV Risk Factor- History of PONV/Motion Sickness MPOG Concept IDs:</th>
</tr>
</thead>
<tbody>
<tr>
<td>70225</td>
</tr>
<tr>
<td>Assessment and Plan - Comments</td>
</tr>
<tr>
<td>70302</td>
</tr>
<tr>
<td>Assessment and Plan- Anesthetic Consideration</td>
</tr>
<tr>
<td>70338</td>
</tr>
<tr>
<td>General- PONV Risk Factors</td>
</tr>
<tr>
<td>70339</td>
</tr>
<tr>
<td>General- PONV Risk Total Score</td>
</tr>
<tr>
<td>70080</td>
</tr>
<tr>
<td>General- Previous Anesthetic Problem</td>
</tr>
<tr>
<td>70102</td>
</tr>
<tr>
<td>Misc- Motion Sickness</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PONV Risk Factor- Intended Administration of Opioids for Postop Analgesia MPOG Concept IDs:</th>
</tr>
</thead>
<tbody>
<tr>
<td>70234</td>
</tr>
<tr>
<td>Assessment and Plan – Postop Pain Management</td>
</tr>
<tr>
<td>10008</td>
</tr>
<tr>
<td>Bupivacaine w/ Hydromorphone 0.1% / Unspecified</td>
</tr>
<tr>
<td>10020</td>
</tr>
<tr>
<td>Alfentanil</td>
</tr>
<tr>
<td>10077</td>
</tr>
<tr>
<td>Bupivacaine w/ Fentanyl 0.0625% / 3 mcg/mL</td>
</tr>
<tr>
<td>10079</td>
</tr>
<tr>
<td>Bupivacaine w/ Fentanyl 0.08% / 2 mcg/mL</td>
</tr>
<tr>
<td>10080</td>
</tr>
<tr>
<td>Bupivacaine w/ Fentanyl 0.125% / 2 mcg/mL</td>
</tr>
<tr>
<td>Code</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>10081</td>
</tr>
<tr>
<td>10082</td>
</tr>
<tr>
<td>10083</td>
</tr>
<tr>
<td>10103</td>
</tr>
<tr>
<td>10186</td>
</tr>
<tr>
<td>10187</td>
</tr>
<tr>
<td>10219</td>
</tr>
<tr>
<td>10258</td>
</tr>
<tr>
<td>10279</td>
</tr>
<tr>
<td>10290</td>
</tr>
<tr>
<td>10306</td>
</tr>
<tr>
<td>10341</td>
</tr>
<tr>
<td>10408</td>
</tr>
<tr>
<td>10414</td>
</tr>
<tr>
<td>10439</td>
</tr>
<tr>
<td>10475</td>
</tr>
<tr>
<td>10476</td>
</tr>
<tr>
<td>10478</td>
</tr>
<tr>
<td>10479</td>
</tr>
<tr>
<td>10481</td>
</tr>
<tr>
<td>10482</td>
</tr>
<tr>
<td>10483</td>
</tr>
<tr>
<td>10486</td>
</tr>
<tr>
<td>10488</td>
</tr>
<tr>
<td>10518</td>
</tr>
<tr>
<td>10519</td>
</tr>
<tr>
<td>10522</td>
</tr>
<tr>
<td>10534</td>
</tr>
<tr>
<td>10536</td>
</tr>
</tbody>
</table>
Data Diagnostics Affected

- Percentage of Cases with Professional Fee Procedure Codes
- Percentage of Cases with Antiemetic Medications
- Percentage of Cases in which the Patient has a known Gender
- Percentage of Intraoperative Notes with a Meaningful Note Mapping
- Percentage of Preoperative Notes with a Meaningful Type Mapping

Phenotypes Used

- Induction End
- Induction Start
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Motion Sickness History Classification
- Nitrous Oxide Used (New) (requires login)
- Obstetric Anesthesia Type
Rationale
Postoperative nausea and vomiting (PONV) is a common and unpleasant outcome of anesthesia care that can lead to other complications, lengthening the patient's recovery period after surgery. Effective management of PONV leads to optimal patient outcomes and comfort during the postoperative period. The Apfel score is one of the most common risk predictors for PONV and is based on 4 variables: female gender, nonsmoking status, history of PONV or motion sickness and postoperative opioid administration. The presence of each additional risk factor increases a patient's risk of PONV by twenty percent. Although including a prophylactic anti-emetic administration protocol that considers such risk factors has shown to reduce the incidence of PONV, there is high variability in this outcome.

References
Measure Abbreviation
PONV-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of patients aged 3 through 17 years of age, who undergo a procedure under general anesthesia in which an inhalational anesthetic is used for maintenance AND who have two or more risk factors for post-operative vomiting (POV), who receive combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively.

The purpose of this process of care measure is to reduce the incidence of postoperative nausea and vomiting in pediatric patients.

Measure Time Period
Preop through Recovery Room In

Inclusions
All patients, age 3 through 17 years of age, who undergo any procedure under general anesthesia in which an inhalational general anesthetic between Anesthesia Start and Anesthesia End is used for maintenance AND who have **two or more risk factors for POV**.

POV Risk Factors:
- Age ≥ 3 years
- History of POV or Post-Operative Nausea and Vomiting (PONV) in patient, parent or sibling
- Strabismus surgery (Indicated by CPT: 00140 or procedure text listed as ‘strab’ ‘eye’ ‘ocular’ or ‘lacrimal’)
- Surgery ≥ 30 minutes

Exclusions
- Patients < 3 or > 17 years old.
- Patients transferred directly to the ICU
- Liver Transplants (see ProcedureTypeTransplantLiver phenotype)
- Lung Transplants (see ProcedureTypeTransplantLung phenotype)
- Procedures on the Neck (CPT 00326)
- Intrathoracic Procedures (CPT 00561)
The recommended pharmacologic anti-emetics for PONV prophylaxis in pediatric patients at risk for moderate to severe PONV include (but may not be limited to):

- 5-Hydroxytryptamine (5-HT3) Receptor Antagonists (Recommended as the first choice for prophylaxis for PONV in children)
- Glucocorticoids
- Anticholinergics
- Antihistamines
- Butyrophenones
- Phenothiazines
- Phenylethylamines
- NK-1 Receptor Antagonists

Note: In addition, propofol infusion is accepted as one of the antiemetic options for this measure. The foregoing list of medications/drug names is based on clinical guidelines and other evidence. The specified drugs were selected based on the strength of evidence for their clinical effectiveness. This list of selected drugs may not be current. Physicians and other health care professionals should refer to the FDA’s web site page entitled “Drug Safety Communications” for up-to-date drug recall and alert information when prescribing medications.

Other Measure Build Details

- For a case to be included for the PONV 02 measure, the patient must have received inhalational general anesthetic for maintenance purposes AND have two or more risk factors for PONV. This measure determines maintenance as any inhalational general anesthetic administered after procedure start (MPOG Concept 50006).
- Values for flows and gases will be assessed and considered artifact if less than the following ranges and the patient did not receive any other inhalational general anesthetics greater than these ranges:
  - Nitrous Oxide Flows: <0.2 L/min
  - Isoflurane Insp %: <0.2%
  - Sevoflurane Insp %: <0.5%
  - Desflurane Insp %: <0.5%
  - Nitrous Oxide Insp % <15%
- All anesthetic gas values prior to Procedure Start are excluded. If no Procedure start, Induction End is used.
- This measure requires CPT codes to be transferred to the MPOG database for cases to be included. Those sites participating with this measure must have current pro fee procedure data in the MPOG.
Algorithm for determining Measure End Time:

1. Recovery Room In Date/Time. If not available then,
2. Phase I Recovery Room In Date/Time. If not available then,
3. Phase II Recovery Room In Date/Time. If not available then,
4. Patient out of Room. If not available then,
5. Data Capture End. If not available then,
6. Anesthesia End.

Algorithm for determining Case Length:

Case Start:

1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Start. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:

1. Patient Extubated. If not available, then
2. LMA Removal Time. If not available, then
3. Procedure End. If not available, then
4. Patient Out of Room. If not available, then
5. Anesthesia End

Responsible Provider

Provider(s) signed in at Induction End.

Method for determining Responsible Provider:

1. Provider signed in at Anesthesia Induction End. If not available then,
2. Provider signed in at Anesthesia Induction Begin. If not available then,
3. Provider signed in at Procedure Start. If not available then,
4. Provider signed in at Patient in Room. If not available then,
5. Provider signed in Anesthesia Start.

Threshold

90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>General Inhalational Anesthetic MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>3297 Enflurane Exp %</td>
</tr>
<tr>
<td>3298 Enflurane Insp %</td>
</tr>
<tr>
<td>3006 Isoflurane actual consumption (ml)</td>
</tr>
<tr>
<td>3007</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>3260</td>
</tr>
<tr>
<td>3265</td>
</tr>
<tr>
<td>3280</td>
</tr>
<tr>
<td>3285</td>
</tr>
<tr>
<td>50420</td>
</tr>
<tr>
<td>3008</td>
</tr>
<tr>
<td>3270</td>
</tr>
<tr>
<td>3275</td>
</tr>
<tr>
<td>3503</td>
</tr>
<tr>
<td>3250</td>
</tr>
<tr>
<td>3255</td>
</tr>
</tbody>
</table>

**Antiemetic MPOG Concept IDs (by class)**

**Class: 5-Hydroxytryptamine (5-HT3) Receptor Antagonists**

<table>
<thead>
<tr>
<th>10335</th>
<th>Ondansetron</th>
</tr>
</thead>
<tbody>
<tr>
<td>10164</td>
<td>Dolasetron</td>
</tr>
<tr>
<td>10208</td>
<td>Granisetron</td>
</tr>
<tr>
<td>10711</td>
<td>Palonosetron</td>
</tr>
</tbody>
</table>

**Anticholinergics**

<table>
<thead>
<tr>
<th>10400</th>
<th>Scopolamine Patch</th>
</tr>
</thead>
<tbody>
<tr>
<td>10399</td>
<td>Scopolamine</td>
</tr>
<tr>
<td>11040</td>
<td>Butylscopolamine</td>
</tr>
</tbody>
</table>

**Antihistamines**

<table>
<thead>
<tr>
<th>10257</th>
<th>Dimenhydrinate</th>
</tr>
</thead>
<tbody>
<tr>
<td>10160</td>
<td>Diphenhydramine</td>
</tr>
<tr>
<td>10635</td>
<td>Meclizine</td>
</tr>
</tbody>
</table>

**Butyrophenones**

<table>
<thead>
<tr>
<th>10169</th>
<th>Droperidol</th>
</tr>
</thead>
<tbody>
<tr>
<td>10210</td>
<td>Haloperidol</td>
</tr>
</tbody>
</table>
### Neurokinin-1 Receptor Agonists

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10035</td>
<td>Aprepitant</td>
</tr>
<tr>
<td>10719</td>
<td>Fosaprepitant</td>
</tr>
</tbody>
</table>

### Phenothiazines

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10374</td>
<td>Promethazine</td>
</tr>
<tr>
<td>10373</td>
<td>Prochlorperazine</td>
</tr>
</tbody>
</table>

### Steroids

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10147</td>
<td>Dexamethasone</td>
</tr>
<tr>
<td>10296</td>
<td>Methylprednisolone</td>
</tr>
</tbody>
</table>

### Prokinetic

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10297</td>
<td>Metoclopramide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10377</td>
<td>Propofol (Infusion only)</td>
</tr>
</tbody>
</table>

### PONV Medical Reason Exclusion MPOG Concept ID

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>50046</td>
<td>Medical Performance Exclusion - PONV</td>
</tr>
</tbody>
</table>

### PONV Risk Factor - History of PONV/Motion Sickness MPOG Concept IDs:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>70225</td>
<td>Assessment and Plan - Comments</td>
</tr>
<tr>
<td>70302</td>
<td>Assessment and Plan - Anesthetic Consideration</td>
</tr>
<tr>
<td>70338</td>
<td>General - PONV Risk Factors</td>
</tr>
<tr>
<td>70339</td>
<td>General - PONV Risk Total Score</td>
</tr>
<tr>
<td>70080</td>
<td>General - Previous Anesthetic Problem</td>
</tr>
</tbody>
</table>

### Data Diagnostics Affected

- Percentage of Cases with Professional Fee Procedure Codes
- Percentage of Cases with Antiemetic Medications
- Percentage of Intraoperative Notes with a Meaningful Note Mapping
- Percentage of Preoperative Notes with a Meaningful Type Mapping

### Phenotypes Used

- Extubation Times
- Induction End
- Induction Start
Rationale
Postoperative nausea and vomiting (PONV) is a common and unpleasant outcome of anesthesia care that can lead to other complications, lengthening the patient’s recovery period after surgery. Effective management of PONV leads to optimal patient outcomes and comfort during the postoperative period. Combination therapy that includes two prophylactic pharmacologic anti-emetic agents of different classes is most effective when managing PONV in children.

A separate PONV risk model should be considered for pediatric patients as many proven risk factors for adults are difficult to assess or do not apply to children. The independent PONV risk factors identified for pediatrics include duration of surgery greater than 30 minutes, age greater than 3 years old, positive history of PONV (individual and/or immediate family) and strabismus surgery. Although including a prophylactic anti-emetic administration protocol that considers such risk factors has shown to reduce the incidence of PONV, there is high variability in this outcome.

References
Measure Abbreviation
PONV-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
PONV 03: Percentage of patients, regardless of age, who undergo a procedure and have a documented nausea/emesis occurrence OR receive a rescue antiemetic in the immediate postoperative period.

PONV 03b: Percentage of patients, regardless of age who undergo a procedure and have a documented nausea/emesis occurrence with or without receiving an antiemetic in the immediate postoperative period.

Measure Time Period
Recovery Room In through 6 hours after Anesthesia End

Inclusions
- All patients, regardless of age, who undergo any procedure including surgical, therapeutic, or diagnostic requiring care by anesthesia providers.
- C-section cases (as determined by the MPOG ‘Obstetric Anesthesia Type’ Phenotype results ‘cesarean section’, ‘cesarean hysterectomy’ and ‘Conversion (cesarean delivery portion)’)

Exclusions
- Patients transferred directly to the ICU
- Organ Harvest (CPT: 01990)
- Liver Transplants (see ProcedureTypeTransplantLiver phenotype)
- Lung Transplants (see ProcedureTypeTransplantLung phenotype)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG ‘Obstetric Anesthesia Type’ Phenotype results ‘Labor Epidural’ and ‘Conversion (Labor Epidural Portion)’)
- Invalid cases where Measure End results prior to Measure Start

Success
Patient does not report nausea, have an emesis event or receive an antiemetic during the immediate postoperative period.
Other Measure Build Details

**Algorithm for determining Measure Start Time:**

1. Recovery Room In Date/Time. If not available then,
2. Phase I Recovery Room In Date/Time. If not available then,
3. Phase II Recovery Room In Date/Time. If not available then,
4. Patient out of Room. If not available then,
5. Data Capture End. If not available then,
6. Anesthesia End.

*If Patient out of Room is used as Measure Start, the measure will begin 1 minute after Measure Start time.

**Algorithm for determining Case Duration:**

**Case Start:**

1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

**Case End:**

1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End

**Responsible Provider**

All providers for a given case who are signed in ≥ 40 minutes. If a given case is ≤ 60 minutes, all providers are responsible.

**Threshold**

10%

**MPOG Concept IDs Required**

**Antiemetic MPOG Concept IDs (by class)**

<table>
<thead>
<tr>
<th>Class: 5-Hydroxytryptamine (5-HT3) Receptor Antagonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>10335</td>
</tr>
<tr>
<td>10164</td>
</tr>
<tr>
<td>10208</td>
</tr>
<tr>
<td>10711</td>
</tr>
</tbody>
</table>

**Antihistamines**

<p>| 10257 | Dimenhydrinate |</p>
<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10160</td>
<td>Diphenhydramine</td>
</tr>
<tr>
<td>10169</td>
<td>Droperidol</td>
</tr>
<tr>
<td>10210</td>
<td>Haloperidol</td>
</tr>
</tbody>
</table>

**Butyrophenones**

**Neurokinin-1 Receptor Agonists**

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10035</td>
<td>Aprepitant</td>
</tr>
<tr>
<td>10719</td>
<td>Fosaprepitant</td>
</tr>
</tbody>
</table>

**Phenothiazines**

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10374</td>
<td>Promethazine</td>
</tr>
<tr>
<td>10373</td>
<td>Prochlorperazine</td>
</tr>
</tbody>
</table>

**Prokinetic**

<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10297</td>
<td>Metoclopramide</td>
</tr>
</tbody>
</table>

**PONV Outcomes MPOG Concept IDs:**

<table>
<thead>
<tr>
<th>ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>50227</td>
<td>GI – Symptoms</td>
</tr>
<tr>
<td>50636</td>
<td>Misc - Patient Vomiting</td>
</tr>
<tr>
<td>50219</td>
<td>Emesis Occurrence</td>
</tr>
<tr>
<td>10503</td>
<td>Emesis</td>
</tr>
<tr>
<td>90010</td>
<td>PONV Assessment</td>
</tr>
<tr>
<td>90371</td>
<td>Postoperative Nausea and/or Vomiting</td>
</tr>
<tr>
<td>90009</td>
<td>PONV Interventions</td>
</tr>
</tbody>
</table>

**Measure Start MPOG Concept IDs**

<table>
<thead>
<tr>
<th>ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>50008</td>
<td>Aacd Patient Out of Room Date/Time</td>
</tr>
<tr>
<td>50010</td>
<td>Aacd Recovery Room In Date/Time</td>
</tr>
<tr>
<td>50066</td>
<td>Phase I Recovery Room In Date/Time</td>
</tr>
<tr>
<td>50068</td>
<td>Phase II Recovery Room In Date/Time</td>
</tr>
<tr>
<td>50379</td>
<td>Monitoring - Automated Physiologic Data Capture Stopped</td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**

- Percentage of Cases with Professional Fee Procedure Codes
- Percentage of Cases with Antiemetic Medications
- Percentage of Cases in which the Patient has a known Gender
- Percentage of Intraoperative Notes with a Meaningful Note Mapping
- Percentage of Preoperative Notes with a Meaningful Type Mapping
Phenotypes Used
- Case Duration
- Measure: PONV-01
- Measure: PONV-02 (PEDS)
- PONVReportedNotes (No phenotype browser page)
- Sex

Rationale
Postoperative nausea and vomiting (PONV) is a common and unpleasant outcome of anesthesia care that can lead to other complications, lengthening the patient’s recovery period after surgery. Effective management of PONV leads to optimal patient outcomes and comfort during the postoperative period. The Apfel score is one of the most common risk predictors for PONV and is based on 4 variables: female gender, non-smoking status, history of PONV or motion sickness and postoperative opioid administration. The presence of each additional risk factor increases a patient’s risk of PONV by twenty percent. Although including a prophylactic anti-emetic administration protocol that considers such risk factors has shown to reduce the incidence of PONV, there is high variability in this outcome. For the purpose of this measure, PONV is defined as administering any rescue medication (antiemetic MPOG Concepts in table below) or documentation of nausea or vomiting in the immediate postoperative period.

Risk Adjustment
Not applicable

References
Measure Abbreviation
PUL-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with median tidal volumes less than 10ml/kg.

Measure Time Period
Case start to Case End (see other measure build details)

Inclusions
Patients undergoing endotracheal intubation.

Exclusions
- ASA 5 and 6 cases
- Patients < 12 years of age
- Patients <20kg.
- Patients ≥ 18 years old with a height <121.9cm (48 in) OR >213.4cm (84 in)
- Patients 12-17 years old with a height <91.4cm (36 in) or >213.4cm (84 in)
- Cases where Epoprostenol is administered as an inhalational agent
- Cases without a documented sex
- Cases without a documented height
- Cases in which patients are mechanically ventilated for less than 45 cumulative minutes.
- One lung ventilation procedures as indicated by intraoperative notes or note details mapped to one of the following MPOG concepts:
  - 50501: Thoracic: Single-lung ventilation
  - 50202: Thoracic: Single-lung ventilation, side detail

Success
Median tidal volume < 10 ml/ kg predicted body weight for the time period between Case Start and Case End

Other Measure Build Details
For a given case, this measure will exclude periods when patients are not under positive pressure ventilation (as defined by Peak Inspiratory Pressure – Positive End Expiratory Pressure ≤ 6).

- Peak Inspiratory Pressure determined by values mapped to MPOG Concept 3185. If no PIP documented, PIP is considered null and tidal volume is included.
- PEEP will be determined using values associated with the following variables:
  1. Use Measured PEEP (MPOG Concept: 3210). If not documented,
  2. Use Set PEEP (MPOG Concept: 3212). If not documented,
  3. Assume PEEP = 0.

For a case to be included for the PUL-01 measure, it must have at least 45 valid values of actual tidal volume or set tidal volume.

In determining median tidal volume, if any value greater than two (2) is documented, it is assumed that tidal volume is documented in milliliters (mL). If all values are less than two (2), tidal volume is assumed to be measured in liters (L).

For patients ≥18 years old with height>121.9cm (48 in) but <213.4cm (84 in), the following equation is used to determine Predicted Body Weight. For patients less than 5 feet, 5 feet (152.4 cm) will be used for the IBW formula:

- Male patients: 50kg + 0.91kg * (height in cm - 152.4)
- Female patients: 45.5kg + 0.91kg * (height in cm - 152.4)

For patients 12-17 years old and height > 91.4cm (36 in) but <213.4cm (84 in), the McLaren Method is used to determine Predicted Body Weight. The McLaren Method is the most commonly used method to determine PBW in children and uses growth charts to determine IBW by identifying the 50th percentile height for age, then using that height to determine 50th percentile weight. This weight is the patient’s Predicted Body Weight (PBW).\(^7\)

“Actual tidal volume” trumps “set tidal volume” if there are at least 45 valid “actual tidal volume” measurements. If there are no values for “actual tidal volume”, “set tidal volume” is used.

Algorithm for determining Case Duration

Case Start:

1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:

1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End

Responsible Provider

Provider signed in for largest portion of case. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.

Method for determining Responsible Provider:

In the event that two or more providers in the same class are signed in for the same duration, all providers signed in for the longest duration will be attributed.
## Threshold

90%

### MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Endotracheal Tube</th>
<th>Tidal Volume</th>
<th>One-Lung Ventilation</th>
<th>Predicted Body Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>50121 Endotracheal Tube Stylet Used</td>
<td>3190 Tidal Volume Actual</td>
<td>50501 Thoracic-Single Lung ventilation</td>
<td>70257 Physical Exam-Height (cm)</td>
</tr>
<tr>
<td>50122 Endotracheal Tube Size</td>
<td>3192 Tidal Volume Set</td>
<td>50202 Thoracic-Single Lung ventilation side detail</td>
<td>70258 Physical Exam-Height (in)</td>
</tr>
<tr>
<td>50123 Endotracheal Tube Type</td>
<td>3185 Peak Inspiratory Pressure</td>
<td>Intraoperative Medication</td>
<td>Administration</td>
</tr>
<tr>
<td>50124 Intubation Endotracheal Tube Secured Mechanism</td>
<td>3210 Positive End Expiratory Pressure-Measured</td>
<td>10473 Epoprost enol</td>
<td>2006 Inhalational</td>
</tr>
<tr>
<td>50125 Endotracheal Tube Secured Distance</td>
<td>3212 Positive End Expiratory Pressure-Set</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50126 Endotracheal Tube Secured Reference Point</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50202 Emergence-Patient Extubated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50205 Intubation Tube Note</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50671 Intubation-endotracheal tube in situ</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Data Diagnostics Affected

- Percentage of Cases with Any Physiologic Observation
- Percentage of Physiologic Observations with a Meaningful Type Mapping
Phenotypes Used

- Anesthesia Technique: General
- ASA Class
- Ideal Body Weight
- MeasureStartingList (requires login)
- PrimaryProvider
- Tidal Volume Actual (Median)
- Tidal Volume Set (Median)
- Ventilation During Intraop
- Weight (kg)

Rationale
The use of lung protective ventilation techniques (low tidal volumes and positive end-expiratory pressure) should be part of standard anesthetic practice for most cases that require positive pressure ventilation. Several randomized controlled trials, as well as a meta-analysis in 2015 describe the benefit with low vs high tidal volume techniques.1-6

References
Measure Abbreviation
PUL-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with median tidal volumes less than or equal to 8 ml/kg.

Measure Time Period
Case Start to Case End (see other measure build details)

Inclusions
Patients undergoing endotracheal intubation.

Exclusions
• ASA 5 and 6 cases
• Patients < 12 years of age
• Patients <20kg.
• Patients ≥ 18 years old with a height <121.9cm (48 in) OR >213.4cm (84 in)
• Patients 12-17 years old with a height <91.4cm (36 in) or >213.4cm (84 in)
• Cases where Epoprostenol is administered as an inhalational agent
• Cases without a documented sex
• Cases without a documented height
• Cases in which patients are mechanically ventilated for less than 45 cumulative minutes.
• One lung ventilation procedures as indicated by intraoperative notes or note details mapped to one of the following MPOG concepts:
  ○ 50501: Thoracic: Single-lung ventilation
  ○ 50202: Thoracic: Single-lung ventilation, side detail

Success
Median tidal volume ≤ 8 ml/ kg predicted body weight for the time period between Case Start and Case End.

Other Measure Build Details
• For a given case, this measure will exclude periods when patients are not under positive pressure ventilation (as defined by Peak Inspiratory Pressure – Positive End Expiratory Pressure ≤ 6).
  ○ Peak Inspiratory Pressure determined by values mapped to MPOG Concept 3185. If no PIP documented, PIP is considered null and tidal volume is included.
  ○ PEEP will be determined using values associated with the following variables:
    1. Use Measured PEEP (MPOG Concept: 3210). If not documented,
    2. Use Set PEEP (MPOG Concept: 3212). If not documented,
    3. Assume PEEP = 0.
• For a case to be included for the PUL-01 measure, it must have at least 45 valid values of actual tidal volume or set tidal volume
• In determining median tidal volume, if any value greater than two (2) is documented, it is assumed that tidal volume is documented in milliliters (mL). If all values are less than two (2), tidal volume is assumed to be measured in liters (L).
• For patients ≥18 years old with height>121.9cm (48 in) but <213.4cm (84 in), the following equation is used to determine Predicted Body Weight. For patients less than 5 feet, 5 feet (152.4 cm) will be used for the IBW formula:
  ○ Male patients: 50kg + 0.91kg * (height in cm - 152.4)
  ○ Female patients: 45.5kg + 0.91kg * (height in cm - 152.4)
• For patients 12-17 years old and height >91.4cm (36 in) but <213.4cm (84 in), the McLaren Method is used to determine Predicted Body Weight. The McLaren Method is the most commonly used method to determine PBW in children and uses growth charts to determine IBW by identifying the 50th percentile height for age, then using that height to determine 50th percentile weight. This weight is the patient’s Predicted Body Weight (PBW).7
• “Actual tidal volume” trumps “set tidal volume” if there are at least 45 valid “actual tidal volume” measurements. If there are no values for “actual tidal volume”, “set tidal volume” is used.

Algorithm for determining Case Duration

Case Start:
1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:
1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End

Responsible Provider

Provider signed in for largest portion of case. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.

Method for determining Responsible Provider:

In the event that two or more providers in the same class are signed in for the same duration, all providers signed in for the longest duration will be attributed.
MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Endotracheal Tube</th>
<th>Tidal Volume</th>
<th>One-Lung Ventilation</th>
<th>Predicted Body Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>50121 Intubation Endotracheal Tube</td>
<td>3190</td>
<td>Tidal Volume</td>
<td>50501 Thoracic-</td>
</tr>
<tr>
<td>Stylet Used</td>
<td>Actual</td>
<td>Single lung</td>
<td>70257 Physical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ventilation</td>
<td>Exam-Height (cm)</td>
</tr>
<tr>
<td>50122 Intubation Endotracheal Tube</td>
<td>3192</td>
<td>Tidal Volume</td>
<td>50202 Thoracic-</td>
</tr>
<tr>
<td>Size</td>
<td>Set</td>
<td>Single lung</td>
<td>70258 Physical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ventilation side</td>
<td>Exam-Height (in)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>detail</td>
<td></td>
</tr>
<tr>
<td>50123 Intubation Endotracheal Tube</td>
<td>3185</td>
<td>Peak Inspiratory</td>
<td>Intraoperative</td>
</tr>
<tr>
<td>Type</td>
<td>Pressure</td>
<td>Medication</td>
<td>Administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50124 Intubation Endotracheal Tube</td>
<td>3210</td>
<td>Positive End</td>
<td>10473 Epoprostenol</td>
</tr>
<tr>
<td>Secured Mechanism</td>
<td>Expiratory</td>
<td>Pressure-</td>
<td>2006 Inhalational</td>
</tr>
<tr>
<td></td>
<td>Pressure</td>
<td>Measured</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50125 Intubation Endotracheal Tube</td>
<td>3212</td>
<td>Positive End</td>
<td>10473 Epoprostenol</td>
</tr>
<tr>
<td>Secured Distance</td>
<td>Expiratory</td>
<td>Pressure-</td>
<td>2006 Inhalational</td>
</tr>
<tr>
<td></td>
<td>Pressure</td>
<td>Set</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50126 Intubation Endotracheal Tube</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secured Reference Point</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50202 Emergence-Patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extubated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50205 Intubation Tube Note</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50671 Intubation - endotracheal tube</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in situ</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data Diagnostics Affected
- Percentage of Cases with Any Physiologic Observation
Rationale

The use of lung protective ventilation techniques (low tidal volumes and positive end-expiratory pressure) should be part of standard anesthetic practice for most cases that require positive pressure ventilation. Several randomized controlled trials, as well as a meta-analysis in 2015 describe the benefit with low vs high tidal volume techniques.\textsuperscript{1-6}

References

Measure Abbreviation
PUL-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases in which Positive End Expiratory Pressure (PEEP) is used for patients undergoing mechanical ventilation during anesthesia. PUL 03 will determine if PEEP was administered (as defined by median PEEP ≥ 2) and also analyze distribution of PEEP levels:

- No PEEP (<2 cm H₂O)
- Low PEEP (2-4 cm H₂O)
- Moderate PEEP (≥ 4 to < 8 cm H₂O)
- High PEEP (≥8 cm H₂O)

Measure Time Period
Case start to case end (see other measure build details)

Inclusions
Patients undergoing endotracheal intubation.

Exclusions
- ASA 5 and 6 cases
- Patients <20kg.
- Cases in which patients are mechanically ventilated for less than 45 cumulative minutes.
- One lung ventilation procedures as indicated by intraoperative notes or note details mapped to one of the following MPOG concepts:
  - 50501: Thoracic: Single-lung ventilation
  - 50202: Thoracic: Single-lung ventilation, side detail

Success
Median PEEP ≥ 2 cm H₂O (Assuming values less than 2 cm H₂O is equivalent to no PEEP administered) for the time period between Case Start and Case End.
Other Measure Build Details

- If no weight is recorded, the case is included.
- For a case to be included, there must be at least 45 cumulative minutes of actual tidal volume or 45 minutes of set tidal volume (if actual is not present).
  - For a given case, this measure will exclude periods when patients are not under positive pressure ventilation (as defined by peak inspiratory pressure – positive end expiratory pressure of ≤ 6).
    - Peak Inspiratory Pressure determined by values mapped to MPOG Concept 3185.
    - PEEP will be determined using values associated with the following variables:
      1. Use Measured PEEP (MPOG Concept: 3210). If not documented,
      2. Use Set PEEP (MPOG Concept: 3212). If not documented,
      3. Assume PEEP = 0.
- Median PEEP will be determined using values associated with the following variables:
  1. Use Measured PEEP. If not documented,
  2. Use Set PEEP. If not documented,
  3. Determine no PEEP data available.
- PEEP values before case start, after case end, and during periods where PIP - PEEP ≤ 6 are not included in calculating the median.

Algorithm for determining Measure Start/End Times:

**Measure Start Time:**

**Case Start**

1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

**Measure End Time:**

**Case End**

1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End

**Responsible Provider**

This measure is informational only. Attribution not yet determined by the MPOG Quality Committee.

**Threshold**

Informational

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Endotracheal Tube</th>
<th>PEEP, PIP, and TV</th>
<th>One Lung Ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure Code</td>
<td>Measure Description</td>
<td>Measure Code</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>50121</td>
<td>Intubation Endotracheal Tube Stylet Used</td>
<td>3210</td>
</tr>
<tr>
<td>50122</td>
<td>Intubation Endotracheal Tube Size</td>
<td>3212</td>
</tr>
<tr>
<td>50123</td>
<td>Intubation Endotracheal Tube Type</td>
<td>3185</td>
</tr>
<tr>
<td>50124</td>
<td>Intubation Endotracheal Tube Secured Mechanism</td>
<td>3190</td>
</tr>
<tr>
<td>50125</td>
<td>Intubation Endotracheal Tube Secured Distance</td>
<td>3192</td>
</tr>
<tr>
<td>50126</td>
<td>Intubation Endotracheal Tube Secured Reference Point</td>
<td></td>
</tr>
<tr>
<td>50202</td>
<td>Emergence- Patient Extubated</td>
<td></td>
</tr>
<tr>
<td>50205</td>
<td>Intubation Tube Note</td>
<td></td>
</tr>
<tr>
<td>50671</td>
<td>Intubation - endotracheal tube in situ</td>
<td></td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**

- Percentage of Cases with Any Physiologic Observation
- Percentage of Physiologic Observations with a Meaningful Type Mapping
- Percentage of Cases with a PEEP Observation
- Percentage of Cases with an Intubation Note
- Percentage of Cases with Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

**Phenotypes Used**

- Age (Years)
- Anesthesia Technique: General
- ASA Class
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- PEEP Actual Median
- PEEP Set Median
- Procedure Type: Non-Operative
- Tidal Volume Actual (Median)
- Tidal Volume Set (Median)
- Ventilation During Intraop
- Weight (kg)
Rationale
The use of lung protective ventilation techniques (low tidal volumes and positive end expiratory pressure) should be part of standard anesthetic practice for most cases that require positive pressure ventilation. Several randomized controlled trials, as well as a meta-analysis in 2015 describe the benefit with low vs high tidal volume techniques and use of PEEP.\textsuperscript{1-6} Unfortunately, there is not enough evidence to suggest specific PEEP levels. Therefore, specific threshold indicators will not be defined for PUL 03 initially.

References
Measure Abbreviation
PAIN-01-Peds

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of patients < 18 years old who undergo a surgical or therapeutic procedure and receive a non-opioid adjunct preoperatively or intraoperatively.

Measure Time Period
Preop Start to Anesthesia End

Inclusions
Patients < 18 years old who undergo any procedure including surgical, therapeutic, or diagnostic requiring care by anesthesia providers.

Exclusions
- Patients ≥ 18 years of age
- ASA 5 and 6
- Cardiac Surgery (CPT: 00560, 00561, 00562, 00563, 00566, 00567, 00580)
- Obstetric Procedures
- Radiology Procedures
- Procedure Type: ECT
- Non-operative procedures
  - Otoscopy (00124)
  - Central Line Placement (00532)
  - Lumbar Puncture (00635)
  - Endoscopy Procedures (00731, 00732, 00740, 00810, 00811, 00812, 00813)
  - Other (01990, 01991, 01992, 01999)
    - Rooms tagged as ‘Other - offsite anesthesia’
    - Cases with procedure text ‘ABR Testing’ (without any additional procedures listed)
- Patients who remained intubated postoperatively (see ‘other measure build details’)
- Spinal, Combined Spinal/Epidural or Unknown Anesthesia Technique: Neuraxial

Success
At least one non-opioid adjunct (medication, regional block, caudal, or epidural) was administered to the patient during the preoperative or intraoperative period.

Other Measure Build Details

- Local anesthetic is captured through medications documented with a route mapped to ‘Local infiltration’ or ‘intradermal’ with medication text including %caine%. Intraop notes mapped to ‘Misc - Local Infiltration of surgical site by surgical team’ are also considered.
- Systemic lidocaine administered via IV infusion is considered as an alternative to regional anesthesia techniques.
- Intramuscular route only valid if used for Ketorolac
- Dexamethasone given alone is not considered a non-opioid adjunct for this measure, because of use for PONV prophylaxis

Algorithm for determining patients who remained intubated postoperatively:

1. Was the patient transported to PACU? If Yes, Include. If No, then
2. Was ExtubationTime prior to Anesthesia End? If Yes, Include. If No or missing, then,
3. Was ‘Emergence - ETT in place, patient manually ventilated’ (ID 50380) documented between procedure end and anesthesia end? If no, Include. If Yes, exclude.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Non-Opioid (Medication)</th>
<th>Neuraxial (Caudal, Epidural, Spinal)</th>
<th>Regional Block</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>B</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>C</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>D</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>E</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>F</td>
<td>No</td>
<td>Spinal/CSE/Unknown</td>
<td>No</td>
</tr>
<tr>
<td>F2</td>
<td>No</td>
<td>Caudal</td>
<td>No</td>
</tr>
<tr>
<td>F3</td>
<td>No</td>
<td>Epidural</td>
<td>No</td>
</tr>
<tr>
<td>F4</td>
<td>No</td>
<td>Neuraxial-Multiple</td>
<td>No</td>
</tr>
<tr>
<td>G</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Responsible Provider

Any provider signed into the case between Anesthesia Start and Anesthesia End

Threshold

None

MPOG Concept IDs Required
<table>
<thead>
<tr>
<th>MPOG Concept ID</th>
<th>Concept Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route</strong></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Intravenous</td>
</tr>
<tr>
<td>2003</td>
<td>Intramuscular (*Ketorolac only)</td>
</tr>
<tr>
<td>2008</td>
<td>Oral</td>
</tr>
<tr>
<td>2009</td>
<td>Nasal</td>
</tr>
<tr>
<td>2023</td>
<td>Enteric Tube</td>
</tr>
<tr>
<td>2012</td>
<td>Rectal</td>
</tr>
<tr>
<td><strong>LOCAL ANESTHETIC</strong></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Local Infiltration (route)</td>
</tr>
<tr>
<td>2027</td>
<td>Intradermal (must contain text ‘-caine’)</td>
</tr>
<tr>
<td>50626</td>
<td>Misc - Local Infiltration of surgical site by surgical team</td>
</tr>
<tr>
<td><strong>ACETAMINOPHEN</strong></td>
<td></td>
</tr>
<tr>
<td>10007</td>
<td>Acetaminophen</td>
</tr>
<tr>
<td>10009</td>
<td>Acetaminophen / Butalbital / Caffeine</td>
</tr>
<tr>
<td>10041</td>
<td>Aspirin / Acetaminophen / Caffeine</td>
</tr>
<tr>
<td><strong>NSAIDS</strong></td>
<td></td>
</tr>
<tr>
<td>10040</td>
<td>Aspirin</td>
</tr>
<tr>
<td>10222</td>
<td>Ibufrofen</td>
</tr>
<tr>
<td>10747</td>
<td>Naproxen</td>
</tr>
<tr>
<td>10116</td>
<td>Celecoxib</td>
</tr>
<tr>
<td><strong>KETOROLAC</strong></td>
<td></td>
</tr>
<tr>
<td>10239</td>
<td>Ketorolac</td>
</tr>
<tr>
<td><strong>KETAMINE</strong></td>
<td></td>
</tr>
<tr>
<td>10238</td>
<td>Ketamine</td>
</tr>
<tr>
<td>10453</td>
<td>PROPOFOL W/ KETAMINE 10 MG/ML + 1 MG/ML</td>
</tr>
<tr>
<td>10572</td>
<td>PROPOFOL W/ KETAMINE 10MG/ML + UNSPECIFIED KETAMINE</td>
</tr>
<tr>
<td>10577</td>
<td>PROPOFOL W/ KETAMINE 10 MG/ML + 0.5 MG/ML</td>
</tr>
<tr>
<td>10578</td>
<td>PROPOFOL W/ KETAMINE 10 MG/ML + 1.5 MG/ML</td>
</tr>
<tr>
<td>10579</td>
<td>PROPOFOL W/ KETAMINE 10 MG/ML + 2 MG/ML</td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Name</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>10149</td>
<td>Dexmedetomidine</td>
</tr>
<tr>
<td>10199</td>
<td>Gabapentin</td>
</tr>
<tr>
<td>10570</td>
<td>Pregabalin</td>
</tr>
<tr>
<td>10132</td>
<td>Clonidine</td>
</tr>
<tr>
<td>10180</td>
<td>Esmolol (*Infusion only)</td>
</tr>
<tr>
<td>10705</td>
<td>Magnesium</td>
</tr>
</tbody>
</table>

**LIDOCAINE (IV Infusion only)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>10477</td>
<td>LIDOCAINE</td>
</tr>
<tr>
<td>10589</td>
<td>LIDOCAINE 0.4%</td>
</tr>
<tr>
<td>10247</td>
<td>LIDOCAINE 0.5%</td>
</tr>
<tr>
<td>10248</td>
<td>LIDOCAINE 1%</td>
</tr>
<tr>
<td>10249</td>
<td>LIDOCAINE 1.5%</td>
</tr>
<tr>
<td>10250</td>
<td>LIDOCAINE 2%</td>
</tr>
<tr>
<td>10691</td>
<td>LIDOCAINE 2% W/ BICARBONATE</td>
</tr>
<tr>
<td>10251</td>
<td>LIDOCAINE 3%</td>
</tr>
<tr>
<td>10252</td>
<td>LIDOCAINE 4%</td>
</tr>
</tbody>
</table>

**REGIONAL BLOCK**

Value Code: 1-22 Peripheral Nerve Blocks

**NEURAXIAL ANESTHESIA**

Value Code: 4 Caudal

Value Code: 2 Epidural

Value Code: 6 Neuraxial - Multiple Types Listed

Value Code: 1,3,5 Spinal, Combined Spinal/Epidural, Neuraxial - Unknown

**PACU PAIN SCORE**

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3086</td>
<td>Pain Score (Generic)</td>
</tr>
<tr>
<td>3087</td>
<td>Pain Score (FLACC)</td>
</tr>
<tr>
<td>3088</td>
<td>Pain Score (Visual Analog Scale)</td>
</tr>
<tr>
<td>3089</td>
<td>Pain Score (Faces)</td>
</tr>
</tbody>
</table>

**Phenotypes Used**

- Anesthesia CPT (Measures)
- Anesthesia Technique: Neuraxial
- Anesthesia Technique: Peripheral Nerve Block
Rationale
Multimodal pain management in children during the perioperative time frame can decrease postoperative pain, improve clinical outcomes, and patient satisfaction after surgery. Opioids hold a prominent role in acute pain management yet carry significant risk of perioperative complications including postoperative nausea and vomiting (PONV), respiratory depression, and increased recovery time after surgery. The American Society of Anesthesiologists (ASA) and Society for Pediatric Anesthesia (SPA) have published guidelines and recommendations which endorse the routine use of multimodal analgesia whenever possible to reduce opioid administration and its side effects. Current evidence supports the use of opioid sparing analgesics in pediatric surgical populations that act through different mechanisms. This list includes (but is not limited to) acetaminophen, NSAIDs, dexamethasone, ketamine, clonidine, and dexmedetomidine.

Risk Adjustment
Not Applicable

References
Measure Abbreviation
PAIN-02

Measure Type
Process

Description
Percentage of patients ≥ 18 years old who undergo a surgical or therapeutic procedure and receive a non-opioid adjunct preoperatively and/or intraoperatively.

Measure Time Period
Preop Start to Anesthesia End

Inclusions
Patients ≥ 18 years old who undergo any procedure including surgical, therapeutic, or diagnostic requiring care by anesthesia providers.

Exclusions
- Patients < 18 years of age
- ASA 5 and 6
- Cardiac Surgery (CPT: 00560, 00561, 00562, 00563, 00566, 00567, 00580)
- Obstetric Procedures
- Radiology Procedures
- Procedure Type: ECT
- Non-operative procedures
  - Otoscopy (00124)
  - Central Line Placement (00532)
  - Lumbar Puncture (00635)
  - Endoscopy Procedures (00731, 00732, 00740, 00810, 00811, 00812, 00813)
  - Other (01990, 01991, 01992, 01999)
    - Rooms tagged as ‘Other - offsite anesthesia’
    - Cases with procedure text ‘ABR Testing’ (without any additional procedures listed)
- Eye Procedures (CPT: 00103, 00140, 00142, 00144, 00147, 00148)
- Patients who remained intubated postoperatively

Success
At least one non-opioid adjunct (medication, regional block, neuraxial block, or local injection) was administered to the patient during the measure time period.

Other Measure Build Details
Local anesthetic is captured through medications documented with a route mapped to ‘Local infiltration’ or
‘intradermal’ with medication text including %caine%. Intraop notes mapped to ‘Misc - Local Infiltration of surgical site by surgical team’ are also considered.

Dexamethasone given alone is not considered a non-opioid adjunct to prevent multiple false positives that may skew measure performance.

**Algorithm for determining patients who remained intubated postoperatively:**

1. Was the patient transported to PACU? If Yes, Include. If No, then
2. Was extubation time prior to Anesthesia End? If Yes, Include. If No or missing, then,
3. Was MPOG concept 50380 ‘Emergence - ETT in place, patient manually ventilated’ documented between procedure end and anesthesia end? If Yes, exclude. If no, Include.

**Responsible Provider**

Any provider signed into the case between Anesthesia Start and Anesthesia End

**Threshold**

None

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>MPOG Concept ID</th>
<th>Concept Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROUTE</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Intravenous</td>
</tr>
<tr>
<td>2008</td>
<td>Oral</td>
</tr>
<tr>
<td>2009</td>
<td>Nasal</td>
</tr>
<tr>
<td>2023</td>
<td>Enteric Tube</td>
</tr>
<tr>
<td>LOCAL ANESTHETIC</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Local Infiltration (route)</td>
</tr>
<tr>
<td>2027</td>
<td>Intradermal (must contain text ‘-caine’)</td>
</tr>
<tr>
<td>50626</td>
<td>Misc - Local Infiltration of surgical site by surgical team</td>
</tr>
<tr>
<td>ACETAMINOPHEN</td>
<td></td>
</tr>
<tr>
<td>10007</td>
<td>Acetaminophen</td>
</tr>
<tr>
<td>NSAIDS</td>
<td></td>
</tr>
<tr>
<td>10222</td>
<td>buprofen</td>
</tr>
<tr>
<td>10747</td>
<td>Naproxen</td>
</tr>
<tr>
<td>10116</td>
<td>Celecoxib</td>
</tr>
<tr>
<td>KETOROLAC</td>
<td></td>
</tr>
</tbody>
</table>
Phenotypes Used

- Anesthesia CPT (Measures)
- Anesthesia Technique: Neuraxial
- Anesthesia Technique: Peripheral Nerve Block
- ASA Class
- Extubation Times
- Is Valid Case (requires login)
- LMA Removal Times
- Measure Staff Sign Ins (requires login)
- Obstetric Anesthesia Type
- PACU End Time
- PACU Start Time
- Postoperative Destination
- Preop Start Time
- Procedure Type: Non-Operative
- xRetiredx Anesthesia Technique: Spinal (requires login)
Rationale
Effective pain management during the perioperative time frame can decrease postoperative pain, improve patient outcomes after surgery. Opioids hold a prominent role in acute pain management yet carry significant risk of perioperative complications including postoperative nausea and vomiting (PONV), respiratory depression, and increased recovery time after surgery. The American Society of Anesthesiologists (ASA) has published guidelines and recommendations which endorse the routine use of multimodal analgesia whenever possible. Current evidence supports the use of opioid sparing analgesics in adult surgical populations that act through different mechanisms. This list includes (but is not limited to) acetaminophen, NSAIDs, ketamine, and clonidine.

Risk Adjustment
NA

References
Measure Abbreviation
SUS-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with mean fresh gas flow (FGF) equal to, or less than 3L/min, during administration of halogenated hydrocarbons and/or nitrous oxide.

SUS01 measures Fresh Gas Flow (FGF) during administration of halogenated hydrocarbons and/or nitrous oxide, as an indirect measure of anesthetic gas waste. For a given case, this measure will include the maintenance period of anesthesia, defined as the time between placement of an endotracheal tube or supraglottic airway and removal of the endotracheal tube or supraglottic airway. This measure will exclude pre-oxygenation (before placement of the airway device) and emergence defined as the time when the fraction of inspired halogenated hydrocarbons and nitrous oxide is 0.

Measure Time Period
Patient Intubated to Patient Extubated

Inclusions
Patients administered halogenated hydrocarbons and/or nitrous oxide, for greater than or equal to 30 minutes from placement of the airway device to removal of the airway device.

Exclusions
- Cases in which halogenated hydrocarbons and nitrous oxide are NOT used
- Cases with maintenance period < 30 minutes
- Cases with >20% of Fresh Gas Flow values manually entered during the case (automated capture of FGF required)
- Cases in which nitric oxide is administered.

Success
Mean FGF equal to, or less than 3L/minute when inspired halogenated hydrocarbons is >0.2%, or nitrous oxide FGF >0.2L/min, during the maintenance period of anesthesia.
Other Measure Build Details

- If Fresh Gas Flow Total (MPOG Concept ID: 3214) is documented for the case, this concept will be used to determine success in the setting of halogenated agents or nitrous oxide use.
- If Fresh Gas Flow Total (MPOG Concept ID: 3214) is not documented for the case, MPOG will calculate Fresh Gas Flow: Flows Oxygen (ID: 3215) + Flows Air (ID: 3220) + Flows Nitrous Oxide (ID: 3225)
- If there are no fresh gas flows documented on the case or the variables are mapped to the incorrect MPOG concept, the case will be excluded. There must be fresh gas flows documented for 80% of the total time the inspired agent is running to be included (minute-by-minute flow values).
- There must be at least 30 minutes of Nitrous Oxide flow >0 L or inspired halogenated hydrocarbons >0% during the maintenance period. Maintenance period is defined as measure start to measure end. See Appendix A for diagram.
- Of the total number of minutes of gas flows documented, at least 80% of the Fresh Gas Flow values must be machine data captured for the case to be included. Any manually entered fresh gas flow or agent values will be included in the calculation of mean FGF if this threshold is met and the case is included.
- If there is a gap in documentation for fresh gas flow values, each value is valid for up to one minute.
- When calculating the mean Fresh Gas Flow, the sum of all flows will be added and divided by the total number of minutes that have a documented gas flow. If there are 30 cumulative minutes of halogenated gas documented, but only 24 minutes of fresh gas flow, the mean will be calculated using the 24 minutes of fresh gas flow. See Appendix B for diagrams depicting how fresh gas flow is calculated within the maintenance period.
- If multiple flow values for oxygen (3215), air (3220), and Nitrous Oxide (3225) occur at different second intervals in the same minute, all values will be aligned to the beginning of the minute and the one documented first will be used. For example, if 1 L/min of oxygen flow was documented at 13:02:30 and 2 L/min of air flow was documented at 13:02:32, both would be assigned 13:02 as the documented time and the total FGF would equal 3 L/min for that minute.
- Values for flows and gases will be assessed and considered artifact if inside the following ranges:
  - Nitrous Oxide Flows: <0.2 L/min
  - Isoflurane Insp %: <0.2%
  - Sevoflurane Insp %: <0.5%
  - Desflurane Insp %: <0.5%
  - Nitrous Oxide Insp % <15%

Algorithm for determining measure start and end:

Measure Start:
1. Placement of endotracheal tube, or supraglottic airway (LMA, COPA), if not available, then
2. Anesthesia Induction End, If not available, then
3. Anesthesia Induction Start. If not available, then
4. Procedure Start. If not available, then
5. Patient in Room. If not available, then
6. Anesthesia Start

Measure End:
1. Patient extubated (see Extubation Time Phenotype) or removal of supraglottic airway (see LMA Removal Time Phenotype). If not available, then
2. Procedure End. If not available
3. Patient Out of Room. If not available, then
4. Anesthesia End.

Responsible Provider
All providers signed in for at least 30 minutes during the time when halogenated agent or nitrous oxide are documented.

Method for determining Responsible Provider:
All providers signed in while patients are administered halogenated hydrocarbons, and/or nitrous oxide, for more than, or equal to, 30 minutes from placement of the airway device to removal of the airway device. See ‘Other Measure Build Details’ section for algorithm for determining measure start and end times.

Threshold
90%

MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Gas Flow MPOG Concepts</th>
<th>Halogenated Agent/Nitrous Oxide</th>
</tr>
</thead>
<tbody>
<tr>
<td>3214 Fresh Gas Flow Total (L/min)</td>
<td>3275 Sevoflurane Insp %</td>
</tr>
<tr>
<td>3225 Flows Nitrous Oxide (L/min)</td>
<td>3265 Isoflurane Insp %</td>
</tr>
<tr>
<td>3220 Flows Air (L/min)</td>
<td>3285 Desflurane Insp %</td>
</tr>
<tr>
<td>3215 Flows Oxygen (L/min)</td>
<td>3250 Nitrous Insp %</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intubation MPOG Concepts</th>
<th>LMA MPOG Concepts</th>
</tr>
</thead>
<tbody>
<tr>
<td>50695 Categorized Note - Intubation</td>
<td>50209 LMA Placement Note</td>
</tr>
<tr>
<td>50117 Intubation/Airway - Approach</td>
<td>50141 Airway - LMA Type</td>
</tr>
<tr>
<td>50205 Intubation Tube Note</td>
<td>50142 Airway - LMA Size</td>
</tr>
<tr>
<td>50121 Intubation ETT Stylet Used</td>
<td>50143 Airway - LMA Placement Difficulty</td>
</tr>
<tr>
<td>50122 Intubation ETT Size</td>
<td>50144 Airway - LMA Placement Technique</td>
</tr>
<tr>
<td>50123 Intubation ETT Type</td>
<td></td>
</tr>
<tr>
<td>50124 Intubation ETT Secured Distance</td>
<td></td>
</tr>
</tbody>
</table>
Data Diagnostics Affected

- Percentage of Cases with Any Physiologic Observations
- Percentage of Physiologic Rows that are Machine Captured
- Percentage of Physiologic Observations with a Meaningful Type Mapping

Phenotypes Used

- Age (Years)
- Anesthesia Technique: General
- Extubation Times
- Induction End
- Induction Start
- Is Valid Case (requires login)
- LMA Removal Times
- Measure Staff Sign Ins (requires login)
- Patient In Room Date/Time
- Patient Out Of Room Date/Time
- Procedure Type: Non-Operative
- Surgery End
- Surgery Start Date/Time

Rationale

Halogenated agents and nitrous oxide leaking or vented into the atmosphere are environmental pollutants. Reducing fresh gas flows can reduce cost of anesthesia without compromising patient care.

References

Measure Abbreviation
TEMP-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases that active warming was administered by the anesthesia provider.

Measure Time Period
Anesthesia Start to Patient Extubated

Inclusions
Cases with general or neuraxial anesthetic technique.

Exclusions
- ASA 5 and 6 cases
- Diagnostic Procedures (CPT: 01922)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- MRI Rooms (Rooms tagged as Radiology-MRI)
- MRI with procedure text:
  - MRI
  - MR Head
  - MR Brain
  - MR Chest
  - MR Torso
  - MR Abdomen
  - MR Lumbar
  - MR Spine
  - MR Knee
  - MR Femur
  - MR Abdomen
  - OFFSITE - RADIOLOGY PROCEDURE
- Cases less than 60 minutes between Case Start and Case End.
Algorithm for determining Case Length:

- **Case Start**
  1. Anesthesia Induction End. If not available, then
  2. Anesthesia Induction Begin. If not available, then
  3. Procedure Start. If not available, then
  4. Patient in Room. If not available, then
  5. Anesthesia Start

- **Case End**
  1. Patient Extubated. If not available, then
  2. Procedure End. If not available, then
  3. Patient Out of Room. If not available, then
  4. Anesthesia End

• Cases where the 'Measure End Time' precedes 'Measure Start Time' will be excluded and marked 'invalid'

Success

• Cases with documentation of an active warming device applied **OR**
• Cases with at least one temperature greater than or equal to 36.0°C within the 30 minutes before case end.
  - **Case End**
    1. Patient Extubated. If not available, then
    2. Procedure End. If not available, then
    3. Patient Out of Room. If not available, then
    4. Anesthesia End

• Other considerations:
  • For patients undergoing cesarean section fluid warmer is accepted as an active warming device.
    - These cases are determined by the MPOG Obstetric Anesthesia Type Phenotype.
    - Included results:
      - 'Conversion (Cesarean Delivery and Labor Epidural Combined)'
      - 'Cesarean Delivery'
      - 'Conversion (Cesarean Delivery Portion)'

Other Measure Build Details

- Artifact algorithm:
  • Less than 32.0°C (89.6°F)
  • Greater than 40.0°C (104.0°F)
  • Any minute-to-minute jumps >0.5°C equivalent.
    - Example: 0.125°C /15s, 0.25°C /30s, 1°C /2mins
  • Conversion from F to C: F=32 +9/5 (°C)
- If temperature site not present in physiologic concept, refer to intraop notes.
- This measure uses the WarmingMethodClassification and WarmingMethodNotes phenotypes, which are not time bound

The active warming (TEMP 01) measure will identify the percentage of cases in which an active warming device was applied between Case Start and Case End or the patient maintained a temperature above 36.0°C without active warming. In the event that the provider opts to not use an active warming device, the case will meet the measure requirements if at least one temperature is greater than or equal to 36.0°C.
within 30 minutes before extubation.

**Active Warming includes:**
- Convective warming: forced air
- Conductive warming: circulating water mattress, resistive heating electrical blankets
- Endovascular warming, using a heat exchanging catheter (very rarely used)
- Radiant heaters

**Passive Warming interventions (NOT active warming):**
- Increasing ambient room temperature
- Thermal insulators such as blankets
- Fluid warmer (except for cesarean section)

**Responsible Provider**
Provider present at induction end.

**Threshold**
90%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Temperature MPOG Concept IDs</th>
<th>Case Time MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>3050 Temp 1- Unspecified Site</td>
<td>50002 AACD Anesthesia Start Date/Time</td>
</tr>
<tr>
<td>3051 Temp 2- Unspecified Site</td>
<td>50003 AACD Patient in Room Date/Time</td>
</tr>
<tr>
<td>3052 Temp 1- Monitoring Site</td>
<td>50004 AACD Induction Start Date/Time</td>
</tr>
<tr>
<td>3053 Temp 2- Monitoring Site</td>
<td>50005 AACD Induction End Date/Time</td>
</tr>
<tr>
<td>3031 Temperature-Temporal Artery</td>
<td>50006 AACD Procedure Start Date/Time</td>
</tr>
<tr>
<td>3054 Temperature-Skin</td>
<td>50007 AACD Procedure Finish Date/Time</td>
</tr>
<tr>
<td>3055 Temperature-Eosophageal</td>
<td>50008 AACD Patient out of room Date/Time</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Blood</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Extubation MPOG Concept IDs</td>
<td></td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Tympanic</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Bladder</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Nasopharyngeal</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Axillary</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Rectal</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature- Myocardial</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Temperature Route</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Monitoring- Temperature Probe Placed</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Monitoring- Temperature Probe Location/Type</td>
</tr>
<tr>
<td>Warming Method Concept IDs</td>
<td></td>
</tr>
<tr>
<td>Date/Time</td>
<td>Patient Warming Method- Convective Warmer</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Warm Room</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Convective Warmer</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Warm Blanket</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Radiant Heaters</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Fluid Warmer</td>
</tr>
<tr>
<td>Date/Time</td>
<td>Warming Attempts- Warmer or blankets location detail</td>
</tr>
</tbody>
</table>

Data Diagnostics Affected
- Percentage of Cases with a Temperature Observation
- Percentage of Cases with an Extubation Note
- Percentage of Cases with Anesthesia Induction End Documented
Phenotypes Used
- Anesthesia Technique: Neuraxial
- ASA Class
- Case Start
- Extubation Times
- Is Valid Case (requires login)
- LMA Removal Times
- Measure Staff Sign Ins (requires login)
- Obstetric Anesthesia Type
- Patient Out Of Room Date/Time
- Procedure Type: MRI
- Procedure Type: Non-Operative
- Surgery End
- Warming Method Classification

Rationale
General and neuraxial anesthesia causes vasodilation thus redistributing body heat from the core to peripheries. This redistribution can cause hypothermia. Core temperatures outside the normal range pose significant risks to patients. Pediatric patients are more likely to develop perioperative hypothermia due to a high surface area to weight ratio and inability to regulate their own temperature.\(^1\) Published research has correlated impaired wound healing, adverse cardiac events, altered drug metabolism, and coagulopathies with unplanned perioperative hypothermia. These adverse outcomes resulted in prolonged hospital stays and increased healthcare expenditures. Active warming techniques provide the best results for reducing cutaneous heat loss and preventing hypothermia.\(^2-7\)

Risk Adjustment
Not applicable.

References


Measure Abbreviation
TEMP-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with increased risk of hypothermia that the anesthesia provider documented at least one core temperature intraoperatively for any patient receiving a general anesthetic.

Measure Time Period
Anesthesia Start to Patient out of Room

Inclusions
All surgical patients receiving general anesthesia

Exclusions
- ASA 5 and 6 cases
- Cases with neuraxial anesthesia as the primary technique
- Cases with regional anesthesia as the primary technique
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- MRI Procedures (as determined by the MPOG 'Procedure Type: MRI' phenotype)
- Cases ≤30 minutes between Case Start and Case End.
- Invalid cases where Measure End results prior to Measure Start

Success
Cases with at least one core temperature documented between Anesthesia Start and Patient out of Room. If not available then, Anesthesia End.

Other Measure Build Details
Core or Near Core Temperature Monitoring Includes:
Pulmonary Artery Temperature
Distal Esophageal Temperature
Nasopharyngeal Temperature
Tympanic Membrane Temperature
Bladder Temperature
Rectal Temperature
Axillary Temperature (arm must be at patient side)
Oral Temperature
Zero-Flux Thermometer Temperature

Peripheral Temperatures (not compliant):
- Skin Temperature
- Temporal Artery Temperature

Artifact algorithm:
- Less than 32.0°C (89.6F)
- Greater than 40.0°C (104.0F)
- Any minute-to-minute jumps >0.5°C equivalent.
  - Example: 0.125°C /15s, 0.25°C / 30s, 1°C / 2mins
- Conversion from F to C: F = 32 +9/5 (°C)

Note: If temperature site is not present in physiologic concept, will refer to intraop notes.

*Algorithm for determining Case Length:

**Case Start**
1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

**Case End**
1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End

**Responsible Provider**
Provider present at induction end.

**Threshold**
90%

**MPOG Concept IDs Required**

<p>| Temperature MPOG Concept IDs | Case Time MPOG Concept IDs |</p>
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3031</td>
<td>Temperature- Temporal Artery</td>
<td>50002</td>
<td>AACD Anesthesia Start Date/Time</td>
</tr>
<tr>
<td>3050</td>
<td>Temp 1- Unspecified Site</td>
<td>50003</td>
<td>AACD Patient in Room Date/Time</td>
</tr>
<tr>
<td>3051</td>
<td>Temp 2- Unspecified Site</td>
<td>50004</td>
<td>AACD Induction Start Date/Time</td>
</tr>
<tr>
<td>3052</td>
<td>Temp 1- Monitoring Site</td>
<td>50005</td>
<td>AACD Induction End Date/Time</td>
</tr>
<tr>
<td>3053</td>
<td>Temp 2- Monitoring Site</td>
<td>50006</td>
<td>AACD Procedure Start Date/Time</td>
</tr>
<tr>
<td>3054</td>
<td>Temperature- Skin</td>
<td>50007</td>
<td>AACD Procedure Finish Date/Time</td>
</tr>
<tr>
<td>3055</td>
<td>Temperature- Esophageal</td>
<td>50008</td>
<td>AACD Patient out of room Date/Time</td>
</tr>
<tr>
<td>3056</td>
<td>Temperature- Blood</td>
<td>50009</td>
<td>AACD Anesthesia End Date/Time</td>
</tr>
<tr>
<td>3057</td>
<td>Temperature- Tympanic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3058</td>
<td>Temperature- Bladder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3059</td>
<td>Temperature- Nasopharyngeal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3060</td>
<td>Temperature- Axillary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3061</td>
<td>Temperature- Rectal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3062</td>
<td>Temperature- Myocardial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3533</td>
<td>Temperature Route</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50191</td>
<td>Monitoring- Temperature Probe Placed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50192</td>
<td>Monitoring- Temperature Probe Location/Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50174</td>
<td>Postoperative Vital Signs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Data Diagnostics Affected**
- Percentage of Cases with a Temperature Observation
- Percentage of Cases with an Extubation Note
- Percentage of Cases with Anesthesia Induction End Documented
- Percentage of Cases with Temperature Location Documented

**Phenotypes Used**
- ASA Class
Rationale
General and neuraxial anesthesia causes vasodilation thus redistributing body heat from the core to peripheries. This redistribution can cause hypothermia. Core temperatures outside the normal range pose significant risks to patients. Pediatric patients are more likely to develop perioperative hypothermia due to a high surface area to weight ratio and inability to regulate their own temperature.\(^1\) Published research has correlated impaired wound healing, adverse cardiac events, altered drug metabolism, and coagulopathies with unplanned perioperative hypothermia. These adverse outcomes resulted in prolonged hospital stays and increased healthcare expenditures. The mortality rate is almost 20% higher only monitoring skin temperature rather than a core temperature for those who experience malignant hyperthermia during surgery.\(^2\) Core temperature measurements are less variable than skin temperature measurements and more accurately represent body temperature.\(^3-5\)

Risk Adjustment
Not applicable.

References


Measure Abbreviation
TEMP-03

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of patients, regardless of age, who undergo surgical or therapeutic procedures under general or neuraxial anesthesia of 60 minutes duration or longer for whom no body temperature was greater than or equal to 36 degrees Celsius (or 96.8 degrees Fahrenheit) recorded within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time.

Measure Time Period
Case Start to Case End

Inclusions
- All patients, regardless of age, who undergo surgical or therapeutic procedures under general or neuraxial anesthesia of 60 minutes duration or longer.

Exclusions
- Cases <60 minutes duration between anesthesia start and anesthesia end.
- MAC cases
- Peripheral Nerve Block only cases
- Radical clavicle or scapula surgery (CPT: 00452)
- Thoracolumbar sympathectomy (CPT: 00622)
- Lumbar chemonucleolysis (CPT: 00634)
- Diagnostic arteriography/venography (CPT: 01916)
- Organ harvest (CPT: 01990)
- Anesthesia for diagnostic or therapeutic nerve blocks/injections (CPT: 01991, 01992)
- Other anesthesia procedure (CPT: 01999)
- Cardiac surgery (CPT: 00561, 00562, 00563, 00566, 00567, 00580, 01920)
- Acute Pain Management (CPT: 01996)
- Obstetric Non-Operative Procedures (CPT: 01958)
- Labor Epidurals (as determined by the MPOG 'Obstetric Anesthesia Type' Phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)')
- Cases with an intraoperative note mapped to intentional hypothermia (MPOG concept: 50037)
Emergency cases (MPOG concepts: 70142 or 515)
Invalid cases where Measure End results prior to Measure Start

Success
At least one body temperature measurement equal to or greater than 36 degrees Celsius (or 96.8 degrees Fahrenheit) achieved within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time. This measure is expressed as an outcome or inverse measure, where a lower score means success.

Other Measure Build Details
Temperature documented in within the postop vital sign note in the anesthetic record or temperatures documented and mapped to the temperature physiologic concepts are acceptable sources for this measure. Conversion from F to C: F=32 +9/5 (°C)
For sites that do not contribute PACU data to ASPIRE, this measure will only capture data documented by the anesthesia provider on the intraoperative anesthetic record.

Artifact algorithm:
- Less than 32.0°C (89.6F)
- Greater than 40.0°C (104.0F)
- Any minute-to-minute jumps >0.5°C equivalent.
  - Example: 0.125°C /15s, 0.25°C / 30s, 1°C / 2mins

Algorithm for determining Case Duration:
Case Start:
1. Anesthesia Induction End. If not available, then
2. Anesthesia Induction Begin. If not available, then
3. Procedure Start. If not available, then
4. Patient in Room. If not available, then
5. Anesthesia Start

Case End:
1. Patient Extubated. If not available, then
2. Procedure End. If not available, then
3. Patient Out of Room. If not available, then
4. Anesthesia End.

Responsible Provider
Provider present for longest duration of the case per staff role. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.
In the event that two or more providers in the same class are signed in for the same duration, all providers signed in for the longest duration will be attributed.

Threshold
<10%
### MPOG Concept IDs Required

<table>
<thead>
<tr>
<th>Temperature MPOG Concept IDs</th>
<th>Exclusion MPOG Concept IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>3050 Temp 1-Unspecified Site</td>
<td>50037 Intentional hypothermia</td>
</tr>
<tr>
<td>3051 Temp 2-Unspecified Site</td>
<td>70142 Assessment and Plan-Emergent Status</td>
</tr>
<tr>
<td>3052 Temp 1-Monitoring Site</td>
<td></td>
</tr>
<tr>
<td>3053 Temp 2-Monitoring Site</td>
<td></td>
</tr>
<tr>
<td>3031 Temperature-Temporal Artery</td>
<td></td>
</tr>
<tr>
<td>3054 Temperature-Skin</td>
<td></td>
</tr>
<tr>
<td>3055 Temperature-Esophageal</td>
<td></td>
</tr>
<tr>
<td>3056 Temperature-Blood</td>
<td></td>
</tr>
<tr>
<td>3057 Temperature-Tympanic</td>
<td></td>
</tr>
<tr>
<td>3058 Temperature-Bladder</td>
<td></td>
</tr>
<tr>
<td>3059 Temperature-Nasopharyngeal</td>
<td></td>
</tr>
<tr>
<td>3060 Temperature-Axillary</td>
<td></td>
</tr>
<tr>
<td>3061 Temperature-Rectal</td>
<td></td>
</tr>
<tr>
<td>50174 Postoperative vital signs</td>
<td></td>
</tr>
</tbody>
</table>

### Data Diagnostics Affected
- Cases with a Temperature Observation
- Cases with Staff Tracking
- Staff Role Mapping
- Staff Sign-Ins are Timed

### Phenotypes Used
- Anesthesia CPT (Measures)
Rationale
Perioperative hypothermia is defined as a core temperature less than 36 degrees Celsius by both the National Institute of Health and Clinical Excellence and the American Heart Association.\textsuperscript{1,2} It is not uncommon for a patient’s core temperature to drop during surgery due to anesthetic induced peripheral vasodilation, exposure of skin during the surgical prep or impaired heat distribution. Pediatric patients are more likely to develop perioperative hypothermia due to a high surface area to weight ratio, minimal subcutaneous fat and inability to regulate their own temperature.\textsuperscript{3} Perioperative hypothermia can result in multiple adverse effects including surgical site infections, cardiovascular events, impaired wound healing and increased hospital length of stay. Such adverse effects are prevented through maintenance of normothermia intraoperatively.\textsuperscript{4-9}

Risk Adjustment
Not applicable.

References
Measure Abbreviation
TRAN-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with a blood transfusion that have a hemoglobin or hematocrit value documented prior to transfusion.

Measure Time Period
Up to 36 hours prior to the first transfusion during the case

Inclusions
All surgical patients receiving anesthetics who receive a transfusion of red blood cells.

Exclusions
- Massive Transfusion: Transfusion of 4 or more units of blood; 4 hours before Anesthesia Start to Anesthesia End.
  - Note for sites that document transfusions in ml instead of units: ASPIRE will default to 350ml/unit.
- EBL ≥ 2000 ml
- Patients < 2 years of age
- Patients <12 years old undergoing a cardiac procedure (CPT: 00560, 00561, 00562, 00563, 00567, 00580).
- Patients <12 years old where either transfused PRBC or EBL was greater than 30cc/kg.
- Burn cases (CPT Codes 01951, 01952, 01953)
- ASA 5 & 6
- Labor Epidurals as determined by the MPOG 'Obstetric Anesthesia Type' phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)'
- Obstetric Non-Operative Procedures - CPT 01958
- Exclude patients with an EBL > 1500cc during cesarean section as determined by MPOG ‘Obstetric Anesthesia Type’ phenotype results:
  - ‘Cesarean Delivery’
  - ‘Cesarean Hysterectomy’
  - ‘Conversion (Cesarean Delivery portion)’
• 'Conversion (Cesarean Hysterectomy portion)'
• 'Conversion (Labor Epidural and Cesarean Delivery Combined)'

- Exclude patients with a HR>110, SBP<85, DBP<45, or O2Sat <95% during cesarean section as determined by MPOG ‘Obstetric Anesthesia Type’ phenotype results:
  - ‘Cesarean Delivery’
  - ‘Cesarean Hysterectomy’
  - ‘Conversion (Cesarean Delivery portion)’
  - ‘Conversion (Cesarean Hysterectomy portion)’
  - 'Conversion (Labor Epidural and Cesarean Delivery Combined)'

- Exclude postpartum hemorrhage cases (ICD-10 code: O72.0, O72.1, O72.2, O72.3)
- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

**Success**

- Documentation of hemoglobin and/or hematocrit prior to blood transfusion

**Considerations:**

- For the first unit of transfusion, a hemoglobin or hematocrit of any value should be checked in a time period of 0 to 90 minutes before the transfusion, or the most recent documented hemoglobin or hematocrit of less than 8/24 should be within 36 hours of the transfusion.
- If the last hemoglobin or hematocrit drawn before the first transfusion is ≤ 5/16, a second unit could be administered without rechecking hemoglobin/hematocrit.
- If multiple units are administered, documentation of a hemoglobin or hematocrit value must be present within 90 minutes before each administration.
- **For pediatric cases (patients < 12 years old):** Pre-transfusion hemoglobin/hematocrit required before the first unit and an additional recheck after 15cc/kg of PRBCs have been administered.
- **For cardiopulmonary bypass cases,** all transfusions administered between cardiopulmonary bypass start and end will not be included for determining measure results for the case.

**Other Measure Build Details**

- Cardiopulmonary bypass (CPB) start/end times defined as follows:
  - Measure will first determine CPB start and end times using the first time associated with one of the following notes and the last time associated with one of the following notes:
    - 50047 Perfusion – Retrograde Arterial Prime/Venous Antegrade Prime Performed (Yes/No)
    - 50399 Cardiopulmonary bypass -- aortic clamp on/off note
    - 50401 Cardiopulmonary bypass vent on - note
    - 50402 Cardiopulmonary bypass vent off - note
    - 50403 Cardiopulmonary bypass vent on detail
    - 50404 Cardiopulmonary bypass vent off detail
    - 50405 Cardiopulmonary bypass rewarm - note
    - 50407 Cardiopulmonary bypass systemic cooling initiated
    - 50409 Cardiopulmonary bypass (full/partial/left-heart) terminated
    - 50410 Cardiopulmonary bypass initiated (full/partial/left-heart)
    - 50411 Cardiopulmonary bypass -- ventilator turned off
    - 50412 Cardiopulmonary bypass -- perfusion start
    - 50413 Cardiopulmonary bypass -- perfusion end
- 50415 Cardiopulmonary bypass -- aortic crossclamp off
- 50416 Cardiopulmonary bypass -- crossclamp and circulatory arrest time totals
- 50417 Cardiopulmonary bypass -- Access cannula removed note
- 50419 Cardiopulmonary bypass -- Aortic crossclamp removal requiring therapy
- 50420 Cardiopulmonary bypass -- Isoflurane vaporizer turned on
- 50421 Cardiopulmonary bypass -- Arterial cannula inserted note
- 50422 Cardiopulmonary bypass -- Arterial cannula insertion site detail
- 50424 Cardiopulmonary bypass -- Blood pressure lowered note
- 50425 Cardiopulmonary bypass -- Blood pressure lowered therapy detail
- 50426 Cardiopulmonary bypass -- Ice off head
- 50427 Cardiopulmonary bypass -- Ice on head
- 50428 Cardiopulmonary bypass - cardioplegia start
- 50429 Cardiopulmonary bypass - cardioplegia stop
- 50647 Cardiopulmonary bypass - Aprotinin test dose performed
- 50714 Cardiopulmonary bypass - Full/partial/left-heart bypass start / stop event
- 50766 Cardiopulmonary bypass -- Circulatory arrest start
- 50767 Cardiopulmonary bypass -- Circulatory arrest stop

Finally, if there are no intraoperative notes available, the measure will review physiologic data mapped to the following variables to determine start and end times as follows:

- At least one of these two cardiac indicators are met:
  - Systolic Blood Pressure (MPOG Concept: 3030) - Diastolic Blood Pressure (MPOG Concept: 3035) < 20 or Pulse (MPOG Concept: 3005) ≤ 5
- At least one of these two pulmonary indicators are met:
  - Respiratory Rate (MPOG Concept: 3580) ≤ 2 or End Tidal CO2 (MPOG Concepts: 3235, 3236) ≤ 5

- Transfusion is defined as:
  - Packed Red Blood Cells-Autologous, Homologous, Unknown Type
  - Whole Blood-Homologous, Unknown Type
  - Categorized Note- Blood Products

- Hematocrit/hemoglobin are defined as:
  - POC - Blood gas-Hct measured, Hemoglobin
  - POC – Hematocrit spun
  - POC – Coulter counter - Hematocrit, Hemoglobin
  - Formal lab - Hematocrit, Hemoglobin
  - Formal lab - Blood gas - Hct measured, Hemoglobin

**Responsible Provider**
Provider(s) who administered blood product

**Threshold**
90%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Blood Product MPOG Concept IDs</th>
<th>Point of Care Testing MPOG Concept IDs</th>
<th>Formal Lab MPOG Concept IDs</th>
<th>EBL MPOG Concept ID</th>
</tr>
</thead>
</table>

*Date Published: 09/2015*
*Date Reviewed: 06/2018*
*Last Updated: 07/30/2021*
Data Diagnostics Affected
- Percentage of Inpatient Cases with Documented Blood Loss
- Percentage of Cases with Documented Blood Transfusions
- Percentage of Fluids with a Meaningful Fluid Mapping
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Cases with a Lab Drawn During Anesthesia
- Percentage of Cases with Point of Care Hematocrit Labs
- Percentage of Cases with Point of Care Hemoglobin Labs
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used
- Anesthesia CPT (Measures)
- ASA Class
- Cardiopulmonary Bypass End
- Cardiopulmonary Bypass Start
- DiagnosesCleaned (No phenotype browser page)
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Obstetric Anesthesia Type
- Procedure Type: Non-Operative
- Total Estimated Blood Loss (EBL)
- Weight (kg)

Rationale
The American Association of Blood Banks (AABB) recommends a transfusion threshold of hemoglobin concentration less than or equal to 8 g/dL or when patient is symptomatic (chest pain, orthostatic hypotension, tachcardia unresponsive to fluid resuscitation, or congestive heart failure). Furthermore,
blood transfusions in non-cardiac surgery have been associated with increased risk of 30-day mortality and morbidity.\(^3\)

Although the literature is not conclusive on the exact hemoglobin concentration that requires transfusion, the evidence is clear that use of fewer RBC transfusions reduces cost and risk for adverse effects of transfusion, and that transfusion for hemoglobin values greater than 10 g/dL is usually not indicated.

TRAN 01 is a process measure focused on measuring hemoglobin or hematocrit prior to transfusion. The rationale for this measure is that the decision to transfuse should include knowledge of the hemoglobin value before administration of blood. Because the literature is not absolutely conclusive on a specific hemoglobin threshold for transfusion, TRAN 01 does not include the actual hemoglobin value as part of the measure.

**Risk Adjustment**

Not applicable

**References**


Measure Abbreviation
TRAN-02

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of cases with a post transfusion hemoglobin or hematocrit value greater than or equal to 10 g/dL or 30%.

Measure Time Period
90 minutes before the last intraoperative transfusion to 18 hours after Anesthesia End

Inclusions
Any patient that receives a red blood cell transfusion. Transfusion is defined as packed red blood cells or whole blood. See MPOG Concept IDs below for complete list.

Exclusions
- Patients < 2 years of age
- Patients <21 years old undergoing a cardiac procedure (CPT: 00560, 00561, 00562, 00563, 00567, 00580)
- Pediatric cases (<12 years old) where either the transfused PRBC or EBL was greater than 30cc/kg.
- ASA 5 & 6
- EBL ≥ 2000ml
- Massive Transfusion: Transfusion of 4 or more units of blood; 4 hours before Anesthesia Start to Anesthesia End
  - Note for sites that document transfusions in ml instead of units: ASPIRE will default to 350ml/unit.
- Labor Epidurals as determined by the MPOG 'Obstetric Anesthesia Type' phenotype results 'Labor Epidural' and 'Conversion (Labor Epidural Portion)'
- Obstetric Non-Operative Procedures - CPT 01958
- Exclude patients with an EBL > 1500cc during cesarean section as determined by MPOG 'Obstetric Anesthesia Type' phenotype results:
  - 'Cesarean Delivery'
  - 'Cesarean Hysterectomy'
  - 'Conversion (Cesarean Delivery portion)'

Date Published: 09/2015
Date Reviewed: 04/2019
Last Updated: 07/30/2021
‘Conversion (Cesarean Hysterectomy portion)’
‘Conversion (Labor Epidural and Cesarean Delivery Combined)’

- Exclude patients with a HR>110, SBP<85, DBP<45, or O2Sat <95% during cesarean section as determined by MPOG ‘Obstetric Anesthesia Type’ phenotype results:
  - ‘Cesarean Delivery’
  - ‘Cesarean Hysterectomy’
  - ‘Conversion (Cesarean Delivery portion)’
  - ‘Conversion (Cesarean Hysterectomy portion)’
  - ‘Conversion (Labor Epidural and Cesarean Delivery Combined)’

- Exclude postpartum hemorrhage cases (ICD-10 code: O72.0, O72.1, O72.2, O72.3)
- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’

**Success**

- Hematocrit value documented as less than or equal to 30% and/or hemoglobin value documented as less than or equal 10 g/dL  **OR**
- No hematocrit or hemoglobin checked within 18 hours of anesthesia end.

**Other Measure Build Details**

- Considerations:
  - All hemoglobin/hematocrit lab values drawn after the last transfusion and within 18 hours after anesthesia end will be evaluated. If the lowest of these values is ≤10g/dL or ≤30%, the case will pass.
  - If the hemoglobin or hematocrit at the time of the last transfusion (within 90 minutes before) is less than or equal to 8/24, the case will pass.

**Responsible Provider**

Individual who administered the transfusion

**Threshold**

<10%

**MPOG Concept IDs Required**

<table>
<thead>
<tr>
<th>Blood Product MPOG Concept IDs</th>
<th>Point of Care Testing MPOG Concept IDs</th>
<th>Formal Lab MPOG Concept IDs</th>
<th>EBL MPOG Concept ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>10489</td>
<td>3415</td>
<td>5005</td>
<td>10499 EBL</td>
</tr>
<tr>
<td>10490</td>
<td>3435</td>
<td>5006</td>
<td></td>
</tr>
<tr>
<td>Packed Red Blood Cells-Homologous</td>
<td>POC-hematocrit spun</td>
<td>Formal lab-Hematocrit</td>
<td></td>
</tr>
</tbody>
</table>
Whole Blood-Homologous

POC- Coulter counter-Hemoglobin

Formal lab-Blood gas-Hct measured

Packed Red Blood Cells- Unknown Type

POC- Coulter counter-Hematocrit

Formal lab-Blood gas-Hemoglobin

Whole Blood-Unknown Type

POC- Blood gas-Hemoglobin

Categorized Note-Blood Products

Data Diagnostics Affected

- Percentage of Inpatient Cases with Documented Blood Loss
- Percentage of Cases with Documented Blood Transfusions
- Percentage of Fluids with a Meaningful Fluid Mapping
- Percentage of Labs Mapped to a Meaningful Lab Mapping
- Percentage of Cases with a Lab Drawn During Anesthesia
- Percentage of Cases with Point of Care Hematocrit Labs
- Percentage of Cases with Point of Care Hemoglobin Labs
- Percentage of Cases with any Staff Tracking
- Percentage of Anesthesia Provider Sign-Ins that are Timed

Phenotypes Used

- Anesthesia CPT (Measures)
- ASA Class
- DiagnosesCleaned (No phenotype browser page)
- Is Valid Case (requires login)
- Measure Staff Sign Ins (requires login)
- Obstetric Anesthesia Type
- Procedure Type: Non-Operative
- Total Estimated Blood Loss (EBL)
- Weight (kg)

Rationale

The American Association of Blood Banks (AABB) recommends a transfusion threshold of hemoglobin concentration less than or equal to 8 g/dL or when patient is symptomatic (chest pain, orthostatic hypotension, tachycardia unresponsive to fluid resuscitation, or congestive heart failure).\(^1\) \(^2\) Furthermore, blood transfusions in non-cardiac surgery have been associated with increased risk of 30-day mortality and morbidity.\(^3\) \(^4\)

Although the literature is not conclusive on the exact hemoglobin concentration that requires transfusion, the evidence is clear that use of fewer RBC transfusions reduces cost and risk for adverse effects of transfusion, and that transfusion to hemoglobin value greater than 10 g/dL or hematocrit greater than 30 is almost always not indicated.\(^5\) TRAN 02 is an outcome measure examining the number of patients who may have received more blood than necessary.
Risk Adjustment
Not applicable

References


Measure Abbreviation
ABX-01

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cesarean deliveries with documentation of antibiotic administration initiated within one hour before surgical incision

Measure Time Period
60 minutes prior to Surgical Incision through Surgical Incision

Inclusions
- Elective, urgent, or emergent cesarean delivery (Determined using the MPOG Obstetric Anesthesia Type phenotype)
- Patients undergoing cesarean section with hysterectomy (As determined by the MPOG Obstetric Anesthesia Type phenotype)

Exclusions
- Obstetric Non-Operative Procedures (Determined using the MPOG Obstetric Anesthesia Type phenotype)
- Cesarean delivery with documentation of infection prior to incision and mapped to one of the following MPOG concepts:
  - 50181 Compliance- Prophylactic Antibiotic Variance Note
  - 50182 Compliance- Prophylactic Antibiotic Variance Note Detail

Success
Documentation of at least one antibiotic administration within one hour of surgical incision. See ‘Other Measure Build Details’ for emergency cases and antibiotic timing exceptions.

Other Measure Build Details

Measure Start Time:
1. 60 minutes before measure end time (see below). For Vancomycin, 120 minutes before measure end time.

**Measure End Time:**

1. 50235 Surgical Incision Time (latest if multiple available), if not available then
2. 50006 AACD Procedure Start Date/Time (latest if multiple available).

- For cases without a documented surgical incision time or procedure start time, the case will be flagged for review.
- For cases with more than one Surgical Incision Time (50235) documented, the latest time will be used. If there is no surgical incision time documented, AACD Procedure Start Date/Time (50006) will be used. If there is more than one procedure start time, the latest procedure start time will be used.

**Acceptable Antibiotics and Associated Timing:**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MPOG Concept</th>
<th>Appropriate Start Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>10048</td>
<td>Within 60 minutes before incision/procedure start through Anesthesia End</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>10107</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Cefepime</td>
<td>10108</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>10109</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Cefotetan</td>
<td>10110</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>10111</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>10114</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>10115</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>10131</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>10202</td>
<td>Within 60 minutes before incision</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>10444</td>
<td>Within 120 minutes before incision</td>
</tr>
</tbody>
</table>

*Any of these antibiotics administered within the timeframe will result in success for this measure focused on antibiotic timing, rather than selection.

- If one of the appropriate antibiotics listed in the table above was given as a bolus in the appropriate time frame, the case will pass and any additional antibiotic infusions will not be considered.
- If only one antibiotic is administered for the case and is documented with infusion start and end times, the following logic will be applied:
  - If the infusion start time **or** infusion end time is within 60 minutes before incision (120 minutes for vancomycin), the case will pass. If the infusion is still running at the time of incision, the case will pass.
  - If the infusion started after or at the same time as incision, the case will be flagged as ‘antibiotic administered late’ unless the case is an emergency case. See last bullet point below for details regarding emergency cases.
  - **Exception:** If azithromycin is started or ends within 60 minutes before incision through anesthesia end, the case will pass.
- Measures will assigned the following results:
- Passed - Antibiotic administered on time
- Flagged - Antibiotic not administered on time
- Flagged - Prophylactic antibiotic administered (Not documented in MAR)
- Flagged - Antibiotic not ordered/indicated per surgeon
- Flagged - Incision/procedure start time documented: No
- Flagged - Antibiotic administered too late
- Flagged - Antibiotic administered too early
- Flagged - Not administered for medical reasons
- Excluded - Scheduled antibiotics/documented infection

- Measure will only look for the prophylactic variance note (50181 or 50182) to be documented if an antibiotic is not documented within the measure time frame.
- For cases with documentation indicating ‘prophylactic antibiotic administered’ (concept ID: 50181 or 50182 or 50622) but the antibiotic(s) administration with dose, route, and time are not documented in the electronic medication administration record will be flagged for review.
- Cases will be flagged for review if there is documentation that an antibiotic was not ordered or there is documentation that the antibiotic is ‘not indicated.’
- For emergency cases, success is determined by documentation of any of the listed antibiotics initiated between 60 minutes before procedure start and anesthesia end. For patients requiring vancomycin, the measure time period for emergency cases is 120 minutes before procedure start and anesthesia end.

**Responsible Provider**

All anesthesia providers signed in at the time of incision. If surgical incision time is not documented (50235) then providers signed in at the procedure start time (50006) will be attributed. If procedure start time (50006) is not documented, then providers signed in at anesthesia start (50002) will be attributed.

**Threshold**

90%

**MPOG Concept IDs Required**

- 50235 Surgical Incision Time
- 50006 AACC Procedure Date/Time
- 10048 Azithromycin
- 10107 Cefazolin
- 10108 Cefepime
- 10109 Cefotaxime
- 10110 Cefotetan
- 10111 Cefoxitin
- 10114 Ceftriaxone
- 10115 Cefuroxime
- 10202 Gentamicin
- 10131 Clindamycin
- 10444 Vancomycin
- 50181 Compliance- Prophylactic Antibiotic Variance Note
Postpartum infections, including endometritis and surgical site infections are common after cesarean deliveries.\(^1\) Smaill & Hofmeyr conducted a large meta-analysis reviewing 81 randomized trials including 11,937 women undergoing elective or nonelective cesarean delivery.\(^6\) The analysis concluded that antimicrobial prophylaxis was associated with reduction in fever, endometritis, urinary tract infection, SSI, and serious infection.\(^6\) Historically, antibiotic prophylaxis was administered after cord clamping during cesarean delivery. However, recent studies suggest that prophylaxis should be administered before surgical incision to decrease the risk of maternal complications with no change in neonatal outcomes.\(^3,5\) Further, the antibiotic should be infused before incision in order to achieve peak antimicrobial concentrations in the tissue at the time of incision.\(^1-2\) Both the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics support the use of single dose prophylaxis administered within 60 minutes before cesarean delivery to prevent maternal infectious morbidity.\(^4\)

**Risk Adjustment**

*Not applicable.*

**References**


Measure Abbreviation
BP 04-OB

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnosis data. This measure is explicitly not based on provider self-attestation.

Measure Type
Process

Description
Percentage of cases with systolic blood pressure <90mmHg for less than or equal to 5 minutes during the time from spinal placement to delivery.

Measure Time Period
Spinal placement to neonate delivery

Inclusions
All cesarean deliveries (as determined using the MPOG Obstetric Anesthesia Type phenotype) with neuraxial anesthesia only (as determined by the Anesthesia Technique-Neuraxial MPOG Phenotype)

Exclusions
- Cesarean delivery patients undergoing general anesthesia- determined using Anesthesia Technique-Neuraxial MPOG phenotype
- Patients undergoing cesarean section with hysterectomy (as determined by the MPOG Obstetric Anesthesia Type Phenotype)
- Emergency cesarean delivery with diagnosis of placental abruption (ICD-10: O45*)
- Rupture of uterus (spontaneous) before onset of labor (ICD-10: O71.0)
- Newborn affected by intrauterine blood loss from ruptured cord (ICD-10: P50.1)
- Abnormal uterine or vaginal bleeding, unspecified (ICD-10: N93.9)
- Placenta previa with hemorrhage, third trimester (ICD-10: O44.13)
- Hemorrhage from placenta previa, antepartum condition or complication (ICD-10: 641.13)
- Hemorrhage from placenta previa, delivered, with or without mention of antepartum condition (ICD-10: 641.11)
- ICD-10 Codes associated with the case and documented from 7 days before to 30 days after the case are considered

Success
SBP <90mmHg for less than or equal to 5 minutes during the time period of spinal placement to delivery
Other Measure Build Details

**Measure Start Time:**

1. For scheduled cesarean delivery cases (as determined by the **Obstetric Anesthesia Type** phenotype):
   - Will use **Neuraxial Start Time (phenotype)**
     1. If Neuraxial Start Time is earlier than ‘Anesthesia Start’, will use ‘Anesthesia Start’
2. For labor epidural cases that are converted to cesarean delivery and are documented as a single case (as determined by the **Obstetric Anesthesia Type** phenotype): Will use the **Cesarean Delivery Start Time for Conversion Cases (phenotype)**
3. For labor epidural cases that are converted to cesarean delivery and documented as two separate cases (as determined by the **Obstetric Anesthesia Type** phenotype): Will use the **Cesarean Delivery Start Time for Conversion Cases (phenotype)**

**Measure End Time (limited to concepts between ‘anesthesia start’ and ‘anesthesia end’):**

1. Delivery of Neonate 2 (50189), if not available
2. Delivery of Neonate (50358), if not available,
3. Oxytocin (10343) Administration Start Time (bolus or infusion), if not available,
4. Obstetrics - Uterine Incision (50357), if not available,
5. AACD Anesthesia End Date/Time (50009)

- Cases where the ‘Measure End Time’ precedes ‘Measure Start Time’ will be excluded and marked ‘invalid’
- **Multiple blood pressures:** Instances where there are two blood pressure monitoring methods, the higher MAP will be used to determine measure compliance.
- **Artifact:** Artifact readings will be identified and removed from final measurement calculation.
  Artifact processing: if systolic and diastolic blood pressures are present, the values must be at least 5 mmHg apart; otherwise the values will be excluded. MAP values less than 10 are excluded.
- Each incidence of hypotension will count for a max of 5 minutes or until ‘Measure End’ (whichever is sooner) if there is a gap in blood pressure measurement
- Use Oxytocin administration start time as determined by oxytocin documented on the case within the measure time period.

**Responsible Provider**
Not applicable- departmental measure only

**Threshold**
90%

**MPOG Concept IDs Required**
- 3011 BP Sys Invasive Unspecified Site 1
- 3012 BP Dias Invasive Unspecified Site 1
- 3013 BP Mean Invasive Unspecified Site 1
- 3015 BP Sys Non-invasive
- 3020 BP Dias Non-invasive
- 3025 BP Mean Non-invasive
Data Diagnostics Affected

- Percentage of cases with a neuraxial note
- Percentage of Physiologic Observations with a Meaningful Type Mapping
- Percentage of Cases with Invasive Blood Pressure
- Percentage of Cases with Non-invasive Blood Pressure
- Percentage of Cases with Physiologic Observations

Phenotypes Used

- Age (Years)
- Blood Pressure Observations
- Cesarean Delivery Start Time for Conversions
- DiagnosesCleaned (No phenotype browser page)
- MeasureStartingList (requires login)
- Obstetric Neuraxial Anesthesia Start Time

Rationale

Neuraxial anesthesia is widely used for cesarean delivery and is associated with lower mortality and morbidity when compared to general anesthesia.\(^5,8,10\) Though overall morbidity is lower, neuraxial anesthesia can lead to maternal hypotension which has been cited as a common maternal complication during cesarean delivery.\(^5-11\) Hypotension can cause fetal acidosis and maternal nausea and vomiting.\(^2,10,12\) Prolonged hypotension can result in organ ischemia, uteroplacental hypoperfusion, loss of consciousness, and cardiovascular collapse.\(^2,8\) Techniques currently used to prevent hypotension related to spinal placement include intravenous fluid prehydration, vasopressor infusions, and less commonly physical methods such as leg elevation and compression stockings.\(^2,5,8,10,11\)

In a Cochrane review of 126 studies including 9565 patients, 94 of the studies defined hypotension as a maternal systolic blood pressure below 80% of baseline recording, absolute value of less than 90 or 100...
mmHg, or some combination thereof.\textsuperscript{2} Patients experiencing severe preeclampsia may be at lower risk of hypotension (but higher risk of other complications) as compared to healthy parturients.\textsuperscript{3} Nonetheless, hypotension and low placental perfusion remain a risk for the preeclamptic patient undergoing neuraxial anesthesia, necessitating the same level of vigilance as for non pre-eclamptic patients.\textsuperscript{3,7}

**Risk Adjustment**

N/a

**References**


Measure Abbreviation
GA 01-OB

Data Collection Method
This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data. This measure is explicitly not based on provider self-attestation.

Measure Type
Outcome

Description
Percentage of cesarean delivery cases where general anesthesia was used

Measure Time Period
Anesthesia Start to Anesthesia End

Inclusions
- Cesarean Delivery cases as determined by the “Obstetric Anesthesia Type” Phenotype. Phenotype results included:
  - Cesarean Delivery
  - Conversion (Cesarean Delivery Portion)
  - Conversion (Labor epidural and cesarean delivery combined)

Exclusions
- Cesarean Hysterectomies as determined by the “Obstetric Anesthesia Type” Phenotype
- Non-cesarean delivery cases

Success
Cesarean delivery completed without use of general anesthesia

Other Measure Build Details
Measure Start Time: Anesthesia Start
Measure End Time: Anesthesia End
- Use of general anesthesia is determined by the ‘Anesthesia Technique: General’ phenotype
- Cases where ‘measure end’ precedes ‘measure start’ will be excluded from the measure
General anesthesia is used in roughly 5% of elective cesarean deliveries and 14-20% of emergent cesarean deliveries.\textsuperscript{1,2} Mothers who receive neuraxial anesthesia report less pain on the day of surgery, show less gastrointestinal stasis, fevers, and coughing on post op day 2, and show earlier mobility and breastfeeding onset than those who receive general anesthesia.\textsuperscript{3} Mothers who receive general anesthesia during cesarean delivery may also be at increased risk of severe postpartum depression as compared to those who receive neuraxial anesthesia.\textsuperscript{4}

References